var title_f31_61_32720="Zephyr Endobronchial Valve end view";
var content_f31_61_32720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Zephyr&reg; Endobronchial Valve, end view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Views of the Zephyr&reg; Endobronchial Valve vents showing an open valve during expiration (panel A) and a closed valve during inspiration (panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strange, C, Herth, FJ, Kovitz, KL, et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 2007; 7:10. Copyright &copy; 2010 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32720=[""].join("\n");
var outline_f31_61_32720=null;
var title_f31_61_32721="Endoloop and hemoclip Endosc";
var content_f31_61_32721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Resection of a pedunculated colonic polyp with a long stalk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) 2 cm polyp in the sigmoid; (B) after passing and retracting the endoscope, the long stalk is demonstrated; (C) the polyp is ensnared with an endoloop; (D) the endoloop is closed to ligate the pedicle; (E) the polyp is snared near to the head; (F) after resection a visible vessel is recognized at the resection site; (G) to achieve definitive hemostasis a hemoclip is placed; (H) final appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32721=[""].join("\n");
var outline_f31_61_32721=null;
var title_f31_61_32722="Rosacea erythema cheek";
var content_f31_61_32722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and telangiectasias are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32722=[""].join("\n");
var outline_f31_61_32722=null;
var title_f31_61_32723="Sulfacetamide (ophthalmic): Drug information";
var content_f31_61_32723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfacetamide (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/55/18292?source=see_link\">",
"    see \"Sulfacetamide (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/13/18643?source=see_link\">",
"    see \"Sulfacetamide (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9523096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bleph&reg;-10;",
"     </li>",
"     <li>",
"      Sulfamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9523097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AK Sulf Liq;",
"     </li>",
"     <li>",
"      Bleph 10 DPS;",
"     </li>",
"     <li>",
"      Diosulf&trade;;",
"     </li>",
"     <li>",
"      PMS-Sulfacetamide;",
"     </li>",
"     <li>",
"      Sodium Sulamyd",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9524090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9523181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conjunctivitis:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ointment: Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     \" (1.25 cm) ribbon into the conjunctival sac of affected eye(s) every 3-4 hours and at bedtime; increase dosing interval as condition responds. Usual duration of treatment: 7-10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: Instill 1-2 drops several times daily up to every 2-3 hours in lower conjunctival sac during waking hours and less frequently at night; increase dosing interval as condition responds. Usual duration of treatment: 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Trachoma:",
"     </b>",
"     Ophthalmic: Solution: Instill 2 drops into the conjunctival sac every 2 hours; must be used in conjunction with systemic therapy",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9523180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/13/18643?source=see_link\">",
"      see \"Sulfacetamide (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Conjunctivitis, trachoma:",
"     </b>",
"     Ophthalmic: Children &gt;2 months: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9523182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9523211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as sodium: 10% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]: 10% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bleph&reg;-10: 10% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfamide: 10% (15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9523099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14637379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact of tube or bottle tip with skin or eye. Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation of solution to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9523100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment and prophylaxis of conjunctivitis and other superficial ocular infections due to susceptible organisms; adjunctive treatment with systemic sulfonamides for therapy of trachoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9523083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bleph&reg;-10 may be confused with Blephamide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9523148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular (following ophthalmic application): Burning, conjunctivitis, conjunctival hyperemia, corneal ulcers, irritation, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9523134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfacetamide, sulfonamides, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9523135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Severe reactions, including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with fulminant hepatic necrosis have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Do not use concurrently with silver preparations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Efficacy: Inactivated by purulent exudates containing PABA; use with caution in severe dry eye. For topical application to the eye only; not for injection.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9523151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9523129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9523130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9523132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9524092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of systemic absorption following ophthalmic administration is not known. Use of systemic sulfonamides while breast-feeding may cause kernicterus in the newborn; the amount of systemic absorption following ophthalmic administration is not known.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9523213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Sulfacetamide Sodium Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (3.5 g): $65.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bleph-10 Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5 mL): $29.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sulfacetamide Sodium Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (15 mL): $55.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9523189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Response to therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9523166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9918 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32723=[""].join("\n");
var outline_f31_61_32723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523096\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523097\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524090\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523181\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523180\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523182\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523211\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523099\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14637379\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523100\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523083\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523148\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523134\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523135\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300089\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523151\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523129\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523130\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523132\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524092\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523213\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523189\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523166\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/55/18292?source=related_link\">",
"      Sulfacetamide (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/13/18643?source=related_link\">",
"      Sulfacetamide (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/42/26276?source=related_link\">",
"      Sulfacetamide (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/37/40531?source=related_link\">",
"      Sulfacetamide (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/16/38147?source=related_link\">",
"      Sulfacetamide (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_61_32724="Pulmonary paragonimiasis";
var content_f31_61_32724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Pulmonary paragonimiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Chest x-ray and computed tomography (CT) on admission.",
"    <br>",
"     (A) Multiple mass-like opacities are shown in the right lung (arrow).",
"     <br>",
"      (B) Multiple nodules with adjacent areas of GGO, suggestive of hemorrhagic metastasis, are observed in both lungs (arrows).",
"      <br>",
"       (C) FDG-PET CT showing increased FDG uptake (max SUV: 3.1) (arrows).",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Kim KU, Lee K, Park HK, et al. A pulmonary paragonimiasis case mimicking metastatic pulmonary tumor. Korean J Parasitol 2011; 49:69. Copyright &copy; 2011.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32724=[""].join("\n");
var outline_f31_61_32724=null;
var title_f31_61_32725="Omeprazole: Patient drug information";
var content_f31_61_32725=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Omeprazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     see \"Omeprazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/23/24952?source=see_link\">",
"     see \"Omeprazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      First&reg;-Omeprazole;",
"     </li>",
"     <li>",
"      PriLOSEC OTC&reg; [OTC];",
"     </li>",
"     <li>",
"      PriLOSEC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Omeprazole&reg;;",
"     </li>",
"     <li>",
"      Losec&reg;;",
"     </li>",
"     <li>",
"      Mylan-Omeprazole;",
"     </li>",
"     <li>",
"      PMS-Omeprazole;",
"     </li>",
"     <li>",
"      PMS-Omeprazole DR;",
"     </li>",
"     <li>",
"      ratio-Omeprazole;",
"     </li>",
"     <li>",
"      Sandoz-Omeprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat ulcers of the swallowing tube (esophagus).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to omeprazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695814",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet (Prilosec OTC&trade;):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694787",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use for more than 14 days. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For patients who have feeding tubes, open the capsule and mix with 3 tablespoons (45 mL) of apple juice. Give in the feeding tube. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Packets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix the",
"       <b>",
"        2.5 mg",
"       </b>",
"       packet contents with 1 teaspoon (5 mL) of water or the",
"       <b>",
"        10 mg",
"       </b>",
"       packet contents with 1 tablespoon (15 mL) of water. Let sit for 2 to 3 minutes, stir, and drink. Rinse cup with more water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect capsules and tablets from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11813 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-72FD83CAD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32725=[""].join("\n");
var outline_f31_61_32725=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203557\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203558\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020630\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020632\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020631\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020636\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020637\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020639\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020634\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020635\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020640\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020641\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=related_link\">",
"      Omeprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/23/24952?source=related_link\">",
"      Omeprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_61_32726="Reducing the costs of medicines";
var content_f31_61_32726=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Reducing the costs of medicines (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/61/32726/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32726/contributors\" id=\"au2571\">",
"       Jonathan M Zand, PharmD BCPS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32726/contributors\" id=\"au7883\">",
"       Becky Briesacher, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/61/32726/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32726/contributors\" id=\"se323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/61/32726/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32726/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32726/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/61/32726?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H18537039\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     When people have a limited income, they sometimes stop taking some or all of the medicines they are supposed to take. For example, people sometimes try to make their medicines last longer by skipping doses or taking smaller doses. That&rsquo;s understandable, given how expensive some medicines are. Unfortunately, people often don&rsquo;t realize that stopping medicines or skipping or lowering doses to save money can cause serious health problems in the long run. Take, for example, people with a condition called coronary heart disease. If they cut back on their medicines, they are more likely to have a heart attack than people who take all their medicines. To make things even more complicated, people who skip or cut back on medicines often end up being prescribed more medicines, because their doctors think that the medicines they prescribed in the first place were not enough (such as with blood pressure or cholesterol medicines) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/61/32726/abstract/1-4\">",
"      1-4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     If you are having trouble paying for your medicines, you should know that there are often ways to make medicines more affordable. If cost is an issue for you, tell your doctor, nurse, or pharmacist. He or she might be able to switch you to a less expensive medicine, or there might be other ways to cut costs, even if you don&rsquo;t have insurance.",
"    </p>",
"    <p>",
"     Don&rsquo;t be embarrassed to bring up money. Many people have trouble affording their medicines. The key to finding a solution is to talk to your doctor, nurse, or pharmacist.",
"    </p>",
"    <p>",
"     The tips for making medicines more affordable described here are meant for people who live in the US, but they might also apply to people in other countries.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537047\">",
"     <span class=\"h1\">",
"      ASK FOR GENERICS",
"     </span>",
"    </p>",
"    <p>",
"     Generic medicines are less expensive copies of brand-name medicines. They contain the same active ingredient as the brand-name medicine they copy, and they are subject to the same government rules about strength and purity.",
"    </p>",
"    <p>",
"     One of the best ways to save money on medicines is to substitute your current brand-name medicines with ones that come as generics whenever it is appropriate to do so. There are a few different situations in which generic medicines might be appropriate for you:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Brand name you take",
"       </strong>",
"       <strong>",
"        comes in generic form",
"       </strong>",
"       &mdash; If the brand-name medicine you take is also sold as a generic, you might be able to take the generic version of that medicine. In many cases, pharmacies will automatically give you the generic version of the brand-name medicine you are prescribed if it is available. For example, if you take the brand-name medicine Lipitor to lower cholesterol or treat a heart condition, an equivalent generic called atorvastatin is now available. The color and shape of generic atorvastatin pills might be different from the brand name version of the pills, but generics are tested to make sure they have the exact same active medicine as Lipitor. (See",
"       <a class=\"local\" href=\"#H18537068\">",
"        'Are generic drugs as safe?'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       <strong>",
"        A medicine in the same &ldquo;class&rdquo; as your brand name comes in a generic form &ndash;",
"       </strong>",
"       Similar medicines are grouped together into &ldquo;classes.&rdquo; All the medicines in one class work in roughly the same way. For example, the medicines in a class called &ldquo;bisphosphonates&rdquo; all slow down loss of bone in about the same way and lower the risk of having a serious hip fracture.",
"       <br/>",
"       <br/>",
"       Sometimes, if one medicine in a class is not sold as a generic, it is possible to take a similar medicine in that class or a related class that is sold as a generic. For example, the bisphosphonate medicines Actonel, Atelvia, and Boniva are sold only by their brand name and can be pretty expensive. If your doctor prescribes one of these, you might be able to take generic Fosamax called &ldquo;alendronate,&rdquo; which is also a bisphosphonate but is available for as little as $4 per month at &ldquo;big&rdquo; retail stores. This saves about $1500 per year on one medicine. (See",
"       <a class=\"local\" href=\"#H18537124\">",
"        'Shop around, buy in bulk'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       <strong>",
"        The brand-name medicine you take comes in a different way that is available as a generic",
"       </strong>",
"       <strong>",
"        &ndash;",
"       </strong>",
"       Some medicines are sold as brand-only because they come with a newer formulation that is still under patent. For example, if you take Coreg CR, a once per day heart medicine, you may be able to switch to generic Coreg, &ldquo;carvedilol,&rdquo; which is taken twice per day. This can save as much as $1600 per year. (See",
"       <a class=\"local\" href=\"#H18537124\">",
"        'Shop around, buy in bulk'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       <strong>",
"        The brand-name medicine you take contains two or more medicines that are each available as a generic &ndash;",
"       </strong>",
"       Sometimes medicines are sold as brand-only because they are the only product that combines two or more ingredients into one pill. In such cases, it&rsquo;s often possible to take the individual ingredients in separate pills.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It&rsquo;s not always possible or appropriate to switch away from a brand name. But when it is appropriate, it can save a lot of money. Any time you replace one medicine for another, make sure you learn what the new medicine looks like and which medicine it is replacing. People sometimes accidentally take the same medicine twice because the brand-name and generic pills look different, and they think they are taking two different medicines. (See",
"     <a class=\"local\" href=\"#H18537082\">",
"      'How do I find out if I can switch to a generic?'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537054\">",
"     <span class=\"h2\">",
"      How much can I save by buying generics?",
"     </span>",
"     &nbsp;&mdash;&nbsp;On average, a 30-day supply of a &ldquo;brand-name&rdquo; prescription medicine costs about $140 a month without insurance coverage. A generic prescription costs about $35 a month without insurance. What&rsquo;s more, the cost of a commonly prescribed generic medicine can be much lower than that, even just $4 per month, if you shop around. That means that switching to the generic could amount to a savings of more than $1,600 a year on just one medicine. (See",
"     <a class=\"local\" href=\"#H18537124\">",
"      'Shop around, buy in bulk'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537061\">",
"     <span class=\"h2\">",
"      Why do generic medicines cost so much less than brand-name drugs?",
"     </span>",
"     &nbsp;&mdash;&nbsp;When drug companies develop a new medicine, they spend a lot of money studying and testing it. They also spend a lot of money on advertising. In exchange for that initial investment, the US government allows drug companies to have a &ldquo;patent&rdquo; on their new medicines. Patents give drug companies the right to be the only ones to sell a medicine for the first several years it is available. Later, when the patent runs out, other companies can come out with generic copies of the medicine.",
"    </p>",
"    <p>",
"     Makers of generic medicines can charge less, because they don&rsquo;t have to pay for developing or advertising the medicines. Still, a generic medicine can only be made and sold in the US after the Food and Drug Administration (FDA) has carefully tested and approved the generic version. Once the FDA tests and approves a generic medicine and the place where it is made, several companies can start making generic copies. At that point, the cost goes down even further, thanks to competition.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537068\">",
"     <span class=\"h2\">",
"      Are generic drugs as safe?",
"     </span>",
"     &nbsp;&mdash;&nbsp;YES. FDA-approved generic medicines meet all of the same requirements for quality, strength, purity, and shelf life as brand-name medicines. Generic manufacturing plants in the US are subject to the same inspections and the same rigid testing as brand manufacturers.",
"    </p>",
"    <p>",
"     For more information about the safety of generic medicines, see the resources section. (See",
"     <a class=\"local\" href=\"#H18537276\">",
"      'FDA information for consumers'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537075\">",
"     <span class=\"h2\">",
"      Do generic drugs work as well as brand-name drugs?",
"     </span>",
"     &nbsp;&mdash;&nbsp;In almost all cases, yes. With very few exceptions, generic medicines can be substituted for the brand-name version and will work just as well. Each FDA-approved generic equivalent drug has been carefully tested and shown to be equivalent to the brand-name version [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/61/32726/abstract/5-7\">",
"      5-7",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Sometimes switching from a brand to a generic or switching between different generic copies could cause problems for a small number of people with certain conditions. That could include people who have difficult-to-treat seizures or thyroid problems, or who take medicines to stop organ rejection after a transplant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537082\">",
"     <span class=\"h2\">",
"      How do I find out if I can switch to a generic?",
"     </span>",
"     &nbsp;&mdash;&nbsp;First, ask your doctor or pharmacist if any of the medicines you take are available as generics. Not all medicines come as generics. (You can check if a brand-name medicine is sold as a generic at this website:",
"     <a class=\"external\" href=\"file://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm\">",
"      www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm",
"     </a>",
"     .) But even if the medicine you take does not come in a generic form, there might be other medicines that can properly treat your condition that do come in a generic form.",
"    </p>",
"    <p>",
"     If you are interested in switching to a generic, the important thing is to work with your doctor and to make changes only with your doctor&rsquo;s approval. Generics are a great cost-saving option, but any time you switch medicines, you have to do it carefully.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537089\">",
"     <span class=\"h2\">",
"      Will I save with generic medicines even if I have insurance?",
"     </span>",
"     &nbsp;&mdash;&nbsp;YES. You can save by using generic medicines even if you have prescription drug coverage or a Medicare Part D prescription plan.",
"    </p>",
"    <p>",
"     Nearly all insurance plans have lower co-pays for generic medicines than they do for brand-name medicines. The co-pay is the amount YOU pay out of pocket each time you fill a prescription when you have prescription drug coverage. Plus, many insurance companies require less paperwork to cover generic medicines, so you can often get generic medicines faster than brand-name ones.",
"    </p>",
"    <p>",
"     But lower co-pays are not the only reason to switch to generics when you have insurance. Many insurances and Medicare Part D plans have a set limit on how much money they will spend on your medicines every year. If you go over that limit, you have to start paying for your medicines on your own. But, if your medicines cost less, you may never reach that limit all year, or at least reach it more slowly. If you&nbsp;reach the coverage limit and have to pay on your own, it will cost you less with generics than with brands. (See",
"     <a class=\"local\" href=\"#H18537145\">",
"      'What if I am eligible for Medicare Part D prescription coverage?'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Some insurance companies also require you to spend a certain amount of your own money on medicines first, before they will start paying for them. The amount you pay first is called a deductible. You can make the most of that deductible by buying generics, if they are appropriate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537096\">",
"     <span class=\"h2\">",
"      What about my non-prescription medicines?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Generic non-prescription (also called &ldquo;over-the-counter,&rdquo; or OTC) medicines are also safe and effective and must be approved by the FDA.",
"    </p>",
"    <p>",
"     Sometimes prescription medicines are sold as non-prescription versions, usually at a lower strength. You should not use those instead of medicines you were prescribed without checking with your doctor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537103\">",
"     <span class=\"h1\">",
"      ASK ABOUT SPLITTING PILLS",
"     </span>",
"    </p>",
"    <p>",
"     If you have NO prescription drug coverage or can spend only a certain amount on prescriptions each year, splitting pills can lower your cost on many commonly used medicines. This is because many prescription medicines cost the same no matter what strength the pill is. As a result, it is sometimes possible to get a prescription for double the strength you need and then to cut the pills in half. That way, you end up getting your medicine at about half the cost [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/61/32726/abstract/8\">",
"      8",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Take the cholesterol-lowering medicine Crestor, for example. It is not sold as a generic, so it is called &ldquo;brand only.&rdquo; A 30-day supply costs about $155 retail if you have no insurance.",
"    </p>",
"    <p>",
"     If your doctor prescribed a typical dose of 10 milligrams a day for you, you could ask your doctor to change the prescription to the 20 milligram Crestor tablet with instructions to take half a pill a day. Then you could cut the pills in half and have enough doses for 60 days instead of 30. Your cost would then be about $78 for a month, saving you $940 a year on one medicine alone. Plus, you would get to stay on the brand-name medicine your doctor prescribed.",
"    </p>",
"    <p>",
"     The cost savings for splitting pills is usually highest for brand-only medicines, like Crestor. But you can also save money by splitting generic medicines. For example, the commonly used cholesterol-lowering medicine simvastatin (brand name: Zocor) is available as a generic. A typical dose is 20 milligrams a day, you can get 40 milligram tablets and take half a pill a day to get your regular dose. This will reduce your cost, even with no insurance coverage, from about $28 a month to $14 a month.",
"    </p>",
"    <p>",
"     If you DO have full prescription coverage, splitting pills is NOT likely to save you money on your usual co-pay.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537110\">",
"     <span class=\"h2\">",
"      Which pills are safe to split?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many pills, including those used to treat high cholesterol, depression, high blood pressure, and diabetes, can be safely split in half by someone with good vision and good use of his or her hands. But it is NOT safe to split ALL medicines. If you split the wrong type of medicine or do it incorrectly, you might get too much medicine too quickly or too little medicine.",
"    </p>",
"    <p>",
"     Flat, round, or oblong pills, and those that have a line down the center for breaking, are easy to split. Medicines that come in capsules or in pills that are designed to release medicines slowly should NOT be split.",
"    </p>",
"    <p>",
"     If you want to try pill splitting, FIRST ask your doctor or pharmacist if it&rsquo;s a good idea. Pill splitting can work only if the pills you take can be safely split and come in a strength that is double the dose you need.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537117\">",
"     <span class=\"h2\">",
"      What is the right way to split a pill?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Always use a pill splitter to split pills. Have your pharmacist show you how to use a pill splitter. A pill splitter is a small, inexpensive plastic device that holds the pill in place and safely cuts it with a small blade (",
"     <a class=\"graphic graphic_figure graphicRef60444 \" href=\"mobipreview.htm?43/1/44051\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     NEVER try to split a pill without a pill splitter. Never use a knife, which can smash your pills, and do not cut more than one or two pills at a time, as split pills can turn to powder if you shake them or store them.",
"    </p>",
"    <p>",
"     If you do end up splitting pills, ALWAYS review the new pill strength and new instructions with your doctor, nurse, or pharmacist to make sure you are getting the right amount of medicine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537124\">",
"     <span class=\"h1\">",
"      SHOP AROUND, BUY IN BULK",
"     </span>",
"    </p>",
"    <p>",
"     Another way to cut the costs of your medicines is to shop around. Find out which pharmacies or stores have the best price. Pharmacies do not all charge the same prices for the same medicines. Plus, many stores and pharmacies offer further discounts for buying in bulk &mdash; 100 pills or more at once. If you know you will be taking a medicine for a while, buying in bulk quantity can mean added savings.",
"    </p>",
"    <p>",
"     BJ&rsquo;s, Costco, Sam&rsquo;s Club, Target, Wal-Mart, and other chain and &ldquo;big&rdquo; retail stores often have good deals on hundreds of generic medicines used to treat common medical conditions. Their prices are often as low as $4 for one month and $10 for three months.",
"    </p>",
"    <p>",
"     You can check to see if the medicines you take are available at these ultra-low prices by asking for a brochure at the pharmacy in the store or by going online. You can find lists of discounted generic medicines for each store by entering the store&rsquo;s name and the words &ldquo;prescription program&rdquo; into Google or another search engine. If the medicine you take is not on the list of low-cost generics at the &ldquo;big&rdquo; stores, print the list and bring it to your doctor at your next appointment. Then ask your doctor if your condition can be treated properly with a medicine that is on the low-cost list. This can save you thousands of dollars a year.",
"    </p>",
"    <p>",
"     It is just as important to price shop for generic medicines as it is for brand medicines. Consumer Reports magazine did a price survey for generic Plavix (called clopidogrel), a medicine commonly used by patients who have had angioplasty or heart stents put in. The magazine found retail prices for a 30-day supply that varied from less than $15 at Costco pharmacies to $175 or more at other pharmacies, such as CVS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/61/32726/abstract/9\">",
"      9",
"     </a>",
"     ].",
"     <strong>",
"      Bottom line, it pays to shop around.",
"     </strong>",
"    </p>",
"    <p>",
"     It is also worth checking and comparing prices at your local pharmacy, not just at the big stores. Some pharmacies will &ldquo;match&rdquo; the best price you find elsewhere in the area, if you ask them. To make shopping around easier, you can usually get a price from a pharmacy over the telephone.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537131\">",
"     <span class=\"h1\">",
"      MAKE THE MOST OF YOUR INSURANCE",
"     </span>",
"    </p>",
"    <p>",
"     If you have insurance, there are lots of things you can do to get the most out of your coverage. First, take the time to learn about your prescription drug coverage so that you can avoid expensive surprises. If you are eligible for Medicare Part D prescription coverage, there are ways to save money with that coverage, too. (See",
"     <a class=\"local\" href=\"#H18537145\">",
"      'What if I am eligible for Medicare Part D prescription coverage?'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If you have a choice between different prescription plans, get the list of medicines that each of the plans covers (called the &ldquo;formulary&rdquo;) and the different co-pay levels (&ldquo;tiers&rdquo;). Most insurance providers have a three-tier system that works like this:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Tier 1 usually has the least expensive co-pay and includes mostly generic medicines.",
"      </li>",
"      <li>",
"       Tier 2 has a higher co-pay than Tier 1 and includes &ldquo;preferred brand-name medicines.&rdquo; These are brand-name medicines that the insurance provider has approved because they are proven to work and be cost effective.",
"      </li>",
"      <li>",
"       Tier 3 has the highest co-pay and includes &ldquo;non-preferred&rdquo; or non-formulary brand-name medicines that &mdash; according to the insurance provider &mdash; can usually be replaced with Tier 1 or Tier 2 medicines without any problems.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     After you get the list of medicines that are covered by your insurance, check if any of the medicines you take are not covered or covered only with a high co-pay or in a limited way. For each of those medicines, ask your insurance company which covered medicines could work for you instead. Then give that information to your doctor.",
"    </p>",
"    <p>",
"     Bring the list of covered medicines and their cost each time you visit a doctor. That way, if you need a new medicine, your doctor can prescribe one that is covered by your insurance at the lower Tier 1 or Tier 2 co-pay. If any of your current medicines are not on the Tier 1 or Tier 2 list or are expensive, ask your doctor if any of the medicines on the list can replace them.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537138\">",
"     <span class=\"h2\">",
"      Should I use the mail-order option?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have prescription drug coverage, most plans offer a mail-order option. This option will save you money on medicines you take for three months or longer. Mail-order is a good idea only after you know for sure that you will be taking a given medicine at a specific dose for at least three months. If you are still changing doses or are not sure if a medicine is going to work for you, you should not buy a three-month supply. If you do and you end up switching to a different medicine or a different dose, you might waste some of the medicine you got.",
"    </p>",
"    <p>",
"     The mail-order pharmacies associated with state-approved prescription drug plans are usually large, reliable, licensed pharmacies that you can use with confidence. Even though they may not be located in your home state, they are licensed to dispense medicines in your state.",
"    </p>",
"    <p>",
"     The mail-order option with prescription drug coverage usually has a discounted co-pay for a 90-day supply of generic medicines and preferred brand medicines. To use this benefit of your insurance, you will need to register for the mail-order option for your plan. You will also need to ask your doctor to write you prescriptions that cover a 90-day supply with each refill. You will need to send the mail-order pharmacy the original prescriptions with a completed form that they provide, or you can have your doctor fax the prescriptions with your form to the mail-order pharmacy. If you decide on the faxing method, it&rsquo;s possible the doctor will have to write your prescriptions on a special fax form provided by the mail-order pharmacy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537145\">",
"     <span class=\"h2\">",
"      What if I am eligible for Medicare Part D prescription coverage?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are eligible for Medicare, you can also enroll in a Medicare Part D prescription plan. There can be as many as 50 different Medicare Part D plans to choose from in your state, and each plan can offer a number of options that can be confusing.",
"    </p>",
"    <p>",
"     A typical Medicare Part D plan costs from about $27 a month to more than $100 a month, depending on the specific coverage provided. The plans vary by many important details, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       How much you have to pay up front before the plan starts paying (called the deductible)",
"      </li>",
"      <li>",
"       The list of covered drugs (called the formulary)",
"      </li>",
"      <li>",
"       The co-pay amounts for generic and preferred brand drugs (called tiers)",
"      </li>",
"      <li>",
"       Whether there is any drug coverage after you exhaust the resources Medicare Part D is willing to spend on you for routine medicines (often called the &ldquo;coverage gap&rdquo; or &ldquo;donut hole&rdquo;)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It takes time to compare the different plans and their options, and it can be tough to decide which Medicare Part D plan is best for your needs. Fortunately, reliable help, even one-on-one personal help, is available. We recommend getting help from the government and non-profit sources listed in the resources section below for Medicare Part D. (See",
"     <a class=\"local\" href=\"#H18537173\">",
"      'Resources'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     We do NOT recommend using a private insurance company&rsquo;s Web site, television ad, or mail ad to select a Medicare Part D plan.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537152\">",
"     <span class=\"h1\">",
"      MAKE SURE YOU NEED ALL THE MEDICINES YOU ARE ON",
"     </span>",
"    </p>",
"    <p>",
"     Some patients are prescribed more medicines than they really need. This seems to happen more often to older adults with multiple medical problems and to people of any age who see different types of doctors for different conditions.",
"    </p>",
"    <p>",
"     In some cases, two different doctors prescribe two or more medicines that do the same thing. To avoid this problem, bring a list of all the medicines you take each time you visit any doctor. On your list, include the dose you use for each medicine, why you use it, how you take it, and the name and type of doctor who prescribed it. An example of such a list can be found at",
"     <a class=\"external\" href=\"file://www.fda.gov/drugs/resourcesforyou/ucm079489.htm\">",
"      www.fda.gov/Drugs/ResourcesForYou/ucm079489.htm",
"     </a>",
"     .",
"    </p>",
"    <p>",
"     Ask all of your doctors to review your medicine list at each visit to make sure the list is up to date and has no errors. For example, your doctors should make sure the list does not include any incorrect doses or any medicines you should have stopped taking. Also check with your doctor that every medicine on your list is still needed and that you are taking it the right way.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537159\">",
"     <span class=\"h1\">",
"      GET HELP PAYING FOR THE MEDICINES YOU NEED",
"     </span>",
"    </p>",
"    <p>",
"     If you already looked into switching to generic medicines, splitting pills, and cutting costs in other ways, but you still can&rsquo;t afford your medicines, you might be able to get help another way. There are state and federal programs that help people pay for their medicines. Plus, there are assistance programs sponsored by non-profit organizations and by drug companies themselves. Whether you can get help from these programs will depend on things such as your income and how many people are in your family. Ask your doctor if these programs are available to you. You can also find information about these programs in the resources section of this article. (See",
"     <a class=\"local\" href=\"#H18537173\">",
"      'Resources'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If you are cared for at a hospital or in a large medical practice, there should be a social worker or a pharmacist there who can help you find programs that might be able to help you.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537166\">",
"     <span class=\"h1\">",
"      BEWARE OF FOREIGN OR INTERNET-ONLY PHARMACIES",
"     </span>",
"    </p>",
"    <p>",
"     Pharmacies based in other countries and ones that exist only online sometimes offer what sound like really good deals. But be careful. Stay away from any pharmacy that offers to sell you prescription medicines without a prescription from a doctor who has actually seen you. The FDA has found that some Internet and foreign pharmacies are not properly licensed and inspected. Plus, they may sell you medicines that are not right for you or that are expired or even fake [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/61/32726/abstract/10-12\">",
"      10-12",
"     </a>",
"     ]. You can find out if an internet pharmacy is licensed in US by checking the FDA website called &ldquo;Know Your Online Pharmacy&rdquo; listed in the resources section in this article. (See",
"     <a class=\"local\" href=\"#H18537276\">",
"      'FDA information for consumers'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Pharmacies in Canada might be reliable, but the FDA has no oversight of their activities, so the agency cannot endorse the use of Canadian pharmacies.",
"    </p>",
"    <p>",
"     There is no need to risk using an Internet-only or foreign pharmacy just to get mail service. There are better ways to shop for low prices and order refills privately and conveniently online. The mail order choice for your prescription plan usually has an online order program. Also, most big chain stores and many local pharmacies now offer free mail-order service and let you order by phone or online at no extra charge. It is much safer to order online from a pharmacy or store that you know and could physically visit if it was necessary.",
"    </p>",
"    <p>",
"     To order prescriptions online from a big store or local pharmacy, ask the pharmacy staff how much your prescriptions will cost if your order that way. Then follow the instructions on their Web site.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18537173\">",
"     <span class=\"h1\">",
"      RESOURCES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537182\">",
"     <span class=\"h2\">",
"      Help with understanding and choosing a Medicare Part D plan",
"     </span>",
"     &nbsp;&mdash;&nbsp;These Web sites are only for people on Medicare.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537190\">",
"     <span class=\"h3\">",
"      Medicare",
"     </span>",
"     &nbsp;&mdash;&nbsp;This is the official government Web site that lists the different drug plans Medicare offers. Here you can compare the plans offered in your state and view each plan&rsquo;s formulary (list of covered drugs).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       General site:",
"       <a class=\"external\" href=\"file://www.medicare.gov/\">",
"        www.medicare.gov",
"       </a>",
"      </li>",
"      <li>",
"       Site with information on state help with drug payment (how to contact each program, who is eligible, and other details you should know):",
"       <a class=\"external\" href=\"https://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx\">",
"        https://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx",
"       </a>",
"      </li>",
"      <li>",
"       Phone: 1-800-MEDICARE (1-800-633-4227)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537197\">",
"     <span class=\"h3\">",
"      Medicare Rights Center",
"     </span>",
"     &nbsp;&mdash;&nbsp;This is an independent non-profit consumer advocacy group that helps people navigate the Medicare system. The group offers a hotline with counselors who can answer questions and help you make the most out of your Medicare coverage.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.medicarerights.org/\">",
"        www.medicarerights.org",
"       </a>",
"      </li>",
"      <li>",
"       Phone: 1-800-333-4114",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537211\">",
"     <span class=\"h3\">",
"      Social Security Extra Help Program",
"     </span>",
"     &nbsp;&mdash;&nbsp;Only for people with Medicare, this official government site has information about the Extra Help program. The Extra Help program helps people pay for the costs &mdash; monthly premiums, annual deductibles, and prescription co-payments &mdash; related to a Medicare prescription drug plan.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.ssa.gov/prescriptionhelp\">",
"        www.ssa.gov/prescriptionhelp",
"       </a>",
"      </li>",
"      <li>",
"       Site with information about applying to the Extra Help program:",
"       <a class=\"external\" href=\"file://www.ssa.gov/pubs/10525.html\">",
"        www.ssa.gov/pubs/10525.html",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537218\">",
"     <span class=\"h3\">",
"      SHIP: State Health Insurance Assistance Program",
"     </span>",
"     &nbsp;&mdash;&nbsp;SHIP is a national program that offers counseling and help to people with Medicare and their families. This site can help you find a counselor in your area who will meet with you one on one and talk to you about your Medicare options.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.shiptalk.org/\">",
"        www.shiptalk.org",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537225\">",
"     <span class=\"h2\">",
"      Help paying for your medicine",
"     </span>",
"     &nbsp;&mdash;&nbsp;These Web sites provide information about different programs to help you pay for medicine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537234\">",
"     <span class=\"h3\">",
"      Benefits Checkup (National Council on Aging)",
"     </span>",
"     &nbsp;&mdash;&nbsp;This site gives people lists of services and programs for which they can apply. The lists include programs to help pay for medicines, but also programs that don&rsquo;t have to do with healthcare directly. For example, this site has information on finding housing, getting food stamps, and finding elder care. You can search for all types of programs at once, or target your search to find a specific kind of service.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.benefitscheckup.org/\">",
"        www.benefitscheckup.org",
"       </a>",
"      </li>",
"      <li>",
"       Phone: 1-800-677-1116",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537241\">",
"     <span class=\"h3\">",
"      Needymeds",
"     </span>",
"     &nbsp;&mdash;&nbsp;This is an independent non-profit organization that provides information about patient assistance from drug companies and the government. The site also offers people a discount card that they can use on prescriptions if they have no insurance or choose not to use their insurance. This card is especially useful in paying for medicines after you reach the Medicare &ldquo;donut hole,&rdquo; and Medicare is no longer paying for your prescriptions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       General site:",
"       <a class=\"external\" href=\"file://www.needymeds.org/\">",
"        www.needymeds.org",
"       </a>",
"      </li>",
"      <li>",
"       Site with state health insurance assistance program (SHIP) information:",
"       <a class=\"external\" href=\"file://www.needymeds.org/indices/ship.htm\">",
"        www.needymeds.org/indices/ship.htm",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537248\">",
"     <span class=\"h3\">",
"      Partnership for Prescription Assistance",
"     </span>",
"     &nbsp;&mdash;&nbsp;This program is run by drug companies and their trade group. It is only for people who do not have prescription drug coverage. The site helps people find programs that will get them medicines for free or for a reduced cost.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.pparx.org/\">",
"        www.pparx.org",
"       </a>",
"      </li>",
"      <li>",
"       Phone: 1-888-4PPA-NOW (1-888-477-2669)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537255\">",
"     <span class=\"h3\">",
"      Rx Assist",
"     </span>",
"     &nbsp;&mdash;&nbsp;This site lets you enter the name of a medicine or the name of a drug company to find programs that can help you get that medicine or medicines made by that company at a reduced cost. In many cases, the online applications for those programs are included.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.rxassist.org/patients\">",
"        www.rxassist.org/patients",
"       </a>",
"      </li>",
"      <li>",
"       Phone: 1-401-729-3284",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537262\">",
"     <span class=\"h3\">",
"      Rx Outreach",
"     </span>",
"     &nbsp;&mdash;&nbsp;This site offers medicines and diabetic treatment supplies at a reduced cost to people who make less than a certain amount of money each year.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Web site:",
"       <a class=\"external\" href=\"file://www.rxoutreach.org/\">",
"        www.rxoutreach.org",
"       </a>",
"      </li>",
"      <li>",
"       Phone: 1-800-769-3880",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537269\">",
"     <span class=\"h2\">",
"      Learn more",
"     </span>",
"     &nbsp;&mdash;&nbsp;These Web sites provide extra information and tips to help you make smart choices and protect your rights when looking for healthcare.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18537276\">",
"     <span class=\"h3\">",
"      FDA information for consumers",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Government sites with information about safety and quality of generic drugs:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       &ldquo;Generic Drugs: Same Medicine, Lower Cost&rdquo;:",
"       <a class=\"external\" href=\"file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm?source=govdelivery\">",
"        file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm?source=govdelivery",
"       </a>",
"      </li>",
"      <li>",
"       &ldquo;Generic Drugs: Questions and Answers&rdquo;:",
"       <a class=\"external\" href=\"file://www.fda.gov/drugs/resourcesforyou/consumers/questionsanswers/ucm100100.htm\">",
"        www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Government sites with information about buying drugs online safely:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       &ldquo;Know your Online Pharmacy&rdquo;:",
"       <a class=\"external\" href=\"file://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm\">",
"        file://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm",
"       </a>",
"      </li>",
"      <li>",
"       &ldquo;Buying Prescription Medicine Online: A Consumer Safety Guide&rdquo;",
"       <br/>",
"       <a class=\"external\" href=\"file://www.fda.gov/Drugs/ResourcesForYou/ucm080588.htm\">",
"        file://www.fda.gov/Drugs/ResourcesForYou/ucm080588.htm",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Government sites with information about the risks of foreign and Internet pharmacies: &nbsp;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       &ldquo;The Possible Dangers of Buying Medicines Over the Internet&rdquo;",
"       <br/>",
"       <a class=\"external\" href=\"file://www.fda.gov/forconsumers/consumerupdates/ucm048396.htm\">",
"        file://www.fda.gov/forconsumers/consumerupdates/ucm048396.htm",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       &ldquo;Buying Medicine from Outside the United States&rdquo;",
"       <br/>",
"       <a class=\"external\" href=\"file://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/buyingmedicinefromoutsidetheunitedstates/default.htm\">",
"        www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/buyingmedicinefromoutsidetheunitedstates/default.htm",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7241754\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7241764\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7241772\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=see_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/47/6899?source=see_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/57/37778?source=see_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=see_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/36/27202?source=see_link\">",
"      Patient information: When you have multiple health problems (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/45/36562?source=see_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=see_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=see_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=see_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/21/26962?source=see_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=see_link\">",
"      Patient information: Liver transplant (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7241831\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7241853\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/61/32726?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/1\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/2\">",
"      Baroletti S, Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation 2010; 121:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/3\">",
"      Roumie CL. The doughnut hole: it's about medication adherence. Ann Intern Med 2012; 156:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/4\">",
"      Mazer M, Bisgaier J, Dailey E, et al. Risk for cost-related medication nonadherence among emergency department patients. Acad Emerg Med 2011; 18:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/5\">",
"      Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009; 43:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/6\">",
"      Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/7\">",
"      Dentali F, Donadini MP, Clark N, et al. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy 2011; 31:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32726/abstract/8\">",
"      Tablet splitting. Med Lett Drugs Ther 2012; 54:63.",
"     </a>",
"    </li>",
"    <li>",
"     Prices on new generic Plavix vary widely, so shop around. ConsumerReports.org 2012. Available at: file://news.consumerreports.org/health/2012/05/prices-on-the-new-generic-plavix-vary-widely-so-shop-around.html (Accessed on September 17, 2012).",
"    </li>",
"    <li>",
"     The Possible Dangers of Buying Medicines over the Internet file://www.fda.gov/forconsumers/consumerupdates/ucm048396.htm (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     BeSafeRx: Know Your Online Pharmacy file://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     FDA takes action against thousands of illegal Internet pharmacies file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm322492.htm (Accessed on October 16, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_61_32726=[""].join("\n");
var outline_f31_61_32726=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537039\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537047\">",
"           ASK FOR GENERICS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537103\">",
"           ASK ABOUT SPLITTING PILLS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537124\">",
"           SHOP AROUND, BUY IN BULK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537131\">",
"           MAKE THE MOST OF YOUR INSURANCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537152\">",
"           MAKE SURE YOU NEED ALL THE MEDICINES YOU ARE ON",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537159\">",
"           GET HELP PAYING FOR THE MEDICINES YOU NEED",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537166\">",
"           BEWARE OF FOREIGN OR INTERNET-ONLY PHARMACIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18537173\">",
"           RESOURCES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7241754\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/1/44051\" title=\"figure 1\">",
"           Pill splitter PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_61_32727="Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis";
var content_f31_61_32727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32727/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/61/32727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15772765\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener's granulomatosis be changed to granulomatosis with polyangiitis (Wegener's), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener's will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), which can be abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), have similar features on renal histology (eg, a focal necrotizing, pauci-immune glomerulonephritis), and have similar outcomes. There are, however, several differences between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with GPA or MPA are initially treated with immunosuppressive therapy to induce remission, most often consisting of glucocorticoids in combination with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Patients who attain remission are then treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , which are less toxic than cyclophosphamide, and low-dose glucocorticoids to maintain the remission. The usual duration of maintenance therapy after stable remission has been induced is 12 to 18 months. More prolonged maintenance therapy should be considered in patients who have multiple disease relapses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapses occur either on maintenance therapy or after maintenance therapy has been discontinued. Patients who have more than minor relapses while on maintenance therapy and relapses occurring in patients who are no longer on maintenance immunosuppression are usually treated with reinstitution of the initial induction regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other therapies that have been evaluated for the induction and maintenance of remission and the treatment of relapses in patients with GPA or MPA will be reviewed here. The clinical manifestations and diagnosis of these disorders, the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant disease, and patient and renal outcomes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3321?source=see_link\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALTERNATIVE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative therapies that have been evaluated as possible treatments for induction, to maintain remission, or treat relapsing disease include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (as maintenance therapy),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16199096\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as initial immunosuppressive therapy in two randomized trials. Rituximab has been established for induction therapy but not maintenance of remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4921599\">",
"    <span class=\"h3\">",
"     Rituximab as initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    with either oral or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    found equivalent efficacy and tolerability, although rituximab was superior in inducing remission in patients with relapsed disease. The data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H16198972#H16198972\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4921621\">",
"    <span class=\"h3\">",
"     Rituximab as maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study reported the results of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      administration to 39 patients who already had induction of complete or partial remission; approximately 90 percent were still being treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/4\">",
"       4",
"      </a>",
"      ]. The rituximab regimen consisted of two 1 g doses given two weeks apart or four weekly doses of 375",
"      <span class=\"nowrap\">",
"       mg/m2,",
"      </span>",
"      followed by 1 g every four months. Rituximab therapy was associated with control of disease activity and allowed reduction or withdrawal of other immunosuppressive agents. Only 3 of 39 patients had non-organ-threatening flares; no patient had organ-threatening disease and there were no recurrences of renal disease, and at two years, the proportion of patients treated with cyclophosphamide had fallen to 30 percent.",
"      <br/>",
"      <br/>",
"      Rituximab was generally well tolerated; two patients developed late onset neutropenia and one patient developed cytomegalovirus colitis.",
"     </li>",
"     <li>",
"      In another study,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      was administered in variable doses as maintenance therapy to 28 patients, most of whom had also received rituximab for induction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/5\">",
"       5",
"      </a>",
"      ]. Organ-threatening relapses occurred in two patients (7 percent), and the drug was generally well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of repeated dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with GPA and MPA is being evaluated in the MAINtenance of remission using RITuximab in Systemic ANca associated vasculitis (MAINRITSAN) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4921664\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used as initial therapy for GPA or MPA, the frequency of adverse events associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    appear to be equivalent. The safety of rituximab as compared with oral (not intravenous) cyclophosphamide has been evaluated through 18 months of follow-up; this is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H16198972#H16198972\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rituximab'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The long-term safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with GPA or MPA has yet to be defined. Limited observational data suggest that rituximab may be associated with a high rate of late-onset neutropenia and severe infections when used to treat GPA, MPA, or other rheumatic diseases. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late-onset neutropenia was noted in 3 of 13 patients (23 percent) with GPA who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and followed for at least 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/7\">",
"       7",
"      </a>",
"      ]. Neutropenia developed a median of 102 days after the final dose of rituximab. The rate of late-onset neutropenia was less in the series mentioned above (5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large series of patients with cryoglobulinemic vasculitis (not GPA or MPA), combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and glucocorticoids was associated with a higher rate of severe infections than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      combined with glucocorticoids (29 versus 7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy, such as infusion reactions, impairment of vaccination responses, and allergic reactions are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, the long-term adverse consequences of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy are well established, and include bone marrow suppression, infertility, and malignancy (bladder cancer, myelodysplasia and acute leukemia), among others. These side effects are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    <span class=\"nowrap\">",
"     (TMP/SMX)",
"    </span>",
"    has generally been regarded as a potential agent for the maintenance of remission rather than as a primary treatment for active disease. The mechanism by which",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    might act in granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA) is uncertain. The induction of disease activity in these disorders has been associated with both infection and the chronic nasal carriage of Staphylococcus aureus, suggesting a possible etiologic role for infection and a possible therapeutic role for antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/9\">",
"     9",
"    </a>",
"    ]. A potential mechanism is that infection-induced cytokine release activates neutrophils, resulting in increased expression of proteinase 3 and myeloperoxidase, the target antigens for ANCA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Granulomatosis with polyangiitis (Wegener's)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Microscopic polyangiitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    in remission maintenance was best evaluated in a double-blind, randomized trial in which 81 patients in remission during or after therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    who were randomly assigned to receive",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    (one double strength tablet [160 mg",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"      trimethoprim",
"     </a>",
"     /800",
"    </span>",
"    mg sulfamethoxazole]) or placebo twice daily for 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/10\">",
"     10",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relapse rate was significantly lower in the active treatment group (18 versus 40 percent in the placebo group; relative risk 0.40). However, the lower rate was only significant in patients with upper respiratory disease; there was no significant difference in the rate of renal or pulmonary (lower respiratory tract) relapse.",
"     </li>",
"     <li>",
"      There was no difference in ANCA titers at any time between the two groups.",
"     </li>",
"     <li>",
"      Twenty percent of patients treated with",
"      <span class=\"nowrap\">",
"       TMP/SMX",
"      </span>",
"      discontinued therapy due to side effects, most of which were minor (anorexia, nausea, rash).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in smaller observational studies: possible efficacy in disease limited to the upper respiratory tract in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/13\">",
"     13",
"    </a>",
"    ] and lack of efficacy in generalized disease",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/14\">",
"      14",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMP/SMX",
"    monotherapy should",
"    <strong>",
"     not",
"    </strong>",
"    be used for the primary treatment of glomerulonephritis or other organ-threatening manifestation of GPA or MPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/15\">",
"     15",
"    </a>",
"    ]. There is some evidence of efficacy in the treatment and maintenance of remission in disease limited to the upper respiratory tract (eg, nasal disease). Furthermore, the dose of",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    used in these trials should be given in lower dose or not used in patients concurrently treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , as this may result in pancytopenia. The dose of",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    should be adjusted for renal insufficiency.",
"   </p>",
"   <p>",
"    The use of",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    for prophylaxis against Pneumocystis carinii pneumonia during induction of remission and the effect of",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    on renal function are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'PCP prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38438?source=see_link&amp;anchor=H8#H8\">",
"     \"Trimethoprim-sulfamethoxazole: An overview\", section on 'Adverse effects and precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) can maintain remissions or treat relapses in patients with GPA or MPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/16-22\">",
"     16-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label trial, 14 patients with GPA in whom remission was induced with daily oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      were subsequently treated with MMF (2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      to maintain remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/17\">",
"       17",
"      </a>",
"      ]. Six patients (43 percent) relapsed at a median of 10 months and no patients had to discontinue MMF because of side effects.",
"     </li>",
"     <li>",
"      A similar rate of relapse was noted in a retrospective study of 29 patients who received MMF for maintenance therapy (48 percent at a mean of 14 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/18\">",
"       18",
"      </a>",
"      ]. This study also evaluated MMF therapy in 22 patients with relapsing disease: 18 attained remission within four months, and 10 relapsed at a mean of 14 months. The mean dose was 1.6",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      MMF was withdrawn in 28 patients because of lack of efficacy in 21, severe adverse events in five and intolerance in 2.",
"     </li>",
"     <li>",
"      Uncontrolled studies have suggested that MMF may be effective in combination with glucocorticoids for patients with relapsing ANCA-associated vasculitis who are resistant to or cannot be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. This was illustrated in a series of 32 such patients who had a median for four relapses; the MMF dose was 1000 mg twice daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/21\">",
"       21",
"      </a>",
"      ]. Cyclophosphamide was considered contraindicated for a variety of reasons including previous hemorrhagic cystitis on cyclophosphamide, treated bladder cancer, bone marrow depression, patient refusal and, in six patients, an incomplete response to or relapse during cyclophosphamide therapy.",
"      <br/>",
"      <br/>",
"      Complete or partial remissions were obtained in 78 and 19 percent, respectively. Relapse during follow-up occurred in 19 of 25 patients (76 percent) who attained complete remission and in all six who attained partial remission. Patients who had previously been treated successfully with cyclophosphamide had a better response than those who had not (complete remission 84 versus 50 percent, relapse 50 versus 100 percent). All but two patients were still taking MMF at the time of relapse and the median time to relapse was similar to the previous median time to relapse (16 versus 17 months). The other two patients relapsed after MMF had been discontinued (at 16 and 41 months) and were successfully treated with a second course of MMF and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is not as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in maintaining remission. This was shown in an open-label, randomized multicenter trial (IMPROVE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/23\">",
"     23",
"    </a>",
"    ]. The IMPROVE trial is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link&amp;anchor=H64742581#H64742581\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Azathioprine versus mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data suggesting efficacy for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the prevention of relapse in ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Cyclosporine does not invariably prevent relapse following renal transplantation, and such relapses can usually be effectively treated by switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Cyclosporine (and other calcineurin inhibitors) use in GPA is further complicated by its potential for nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=see_link&amp;anchor=H21#H21\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has uncertain efficacy as maintenance therapy in GPA and is NOT recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    , a TNFa modulatory agent, has been examined for maintenance therapy following induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in patients with GPA. The Wegener's Granulomatosis Etanercept Trial (WGET) included 180 patients who attained remission with standard induction therapy (glucocorticoids plus cyclophosphamide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/27\">",
"     27",
"    </a>",
"    ]. After attaining remission, patients were tapered from usual therapy and randomly assigned to etanercept or placebo.",
"   </p>",
"   <p>",
"    At a mean follow-up of 27 months, the two groups did not differ in their rates of sustained remission (approximately 72 percent), time to sustained remission, risk of disease flares, and rates of prolonged periods of decreased disease activity. There was a high rate of complications among all patients (56 to 57 percent in both groups), and only 50 percent of the patients achieved and maintained their remissions throughout the trial.",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    was ineffective for the maintenance of disease remission in GPA. In addition, etanercept was associated with a significantly higher number of solid tumors (six versus zero for placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only immunosuppressive drugs for which there are standardized prospective trial data establishing efficacy for induction and maintenance of remission in granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA) are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . More than minor relapses are usually treated with a cyclophosphamide-based or rituximab-based induction regimen.",
"   </p>",
"   <p>",
"    Other drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (or other calcineurin inhibitors), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , should only be considered in patients who do not tolerate or have relative contraindications to conventional therapies. Current information on these therapies remains too limited to draw firm conclusions, and their use must be guided by individual patient circumstances. Full dose",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    should NOT be used in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    given the risk of pancytopenia.",
"   </p>",
"   <p>",
"    By comparison,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    does not appear to be effective in sustaining remission and, when used in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , is associated with an increased risk of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32727/abstract/27\">",
"     27",
"    </a>",
"    ]. As a result, etanercept should",
"    <strong>",
"     not",
"    </strong>",
"    be used for the treatment of GPA.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/4\">",
"      Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/5\">",
"      Roubaud-Baudron C, Pagnoux C, M&eacute;aux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/6\">",
"      Jayne D. Rituximab treatment for vasculitis. Clin J Am Soc Nephrol 2010; 5:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/7\">",
"      Tesfa D, Ajeganova S, H&auml;gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/8\">",
"      Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012; 119:5996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/9\">",
"      Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/10\">",
"      Stegeman, CA, Cohen Tervaert, JW, de Jong, PE, Kallenberg, CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/11\">",
"      Israel HL. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 1988; 148:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/12\">",
"      Valeriano-Marcet J, Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991; 151:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/13\">",
"      Hoffman GS. Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/14\">",
"      Reinhold-Keller E, De Groot K, Rudert H, et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996; 89:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/15\">",
"      Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/16\">",
"      Nowack R, G&ouml;bel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/17\">",
"      Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/18\">",
"      Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006; 102:c100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/19\">",
"      Ibernon M, Poveda R, Vidaller A, et al. Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity. Clin Nephrol 2008; 69:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/20\">",
"      Iatrou C, Zerbala S, Revela I, et al. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol 2009; 72:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/21\">",
"      Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/22\">",
"      Joy MS, Hogan SL, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/23\">",
"      Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/24\">",
"      Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/25\">",
"      Allen NB, Caldwell DS, Rice JR, McCallum RM. Cyclosporin A therapy for Wegener's granulomatosis. Adv Exp Med Biol 1993; 336:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/26\">",
"      Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol 2002; 13:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/27\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32727/abstract/28\">",
"      Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3097 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32727=[""].join("\n");
var outline_f31_61_32727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15772765\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALTERNATIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16199096\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4921599\">",
"      - Rituximab as initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4921621\">",
"      - Rituximab as maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4921664\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24824?source=related_link\">",
"      Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3321?source=related_link\">",
"      Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38438?source=related_link\">",
"      Trimethoprim-sulfamethoxazole: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_61_32728="External carotid artery anatomy";
var content_f31_61_32728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    External carotid artery anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    External carotid artery and its branches in the lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32728=[""].join("\n");
var outline_f31_61_32728=null;
var title_f31_61_32729="Meniere disease";
var content_f31_61_32729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Meniere disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Elizabeth A Dinces, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Steven D Rauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32729/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/61/32729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meniere disease is a condition that is thought to arise from abnormal fluid and ion homeostasis in the inner ear. The disease is named for Prospere Meniere, a French physician who first reported that the inner ear could be the source of a syndrome manifesting episodic vertigo, tinnitus, and hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic pathologic lesion of Meniere disease is termed endolymphatic hydrops. This lesion can be definitively diagnosed only by postmortem histopathologic analysis of the temporal bone. However, hydrops has also been identified in postmortem examination of temporal bones where there was no history of Meniere symptoms.",
"   </p>",
"   <p>",
"    Meniere disease refers to presentation of the typical set of symptoms with an idiopathic etiology. The symptomatic triad may also occur secondary to other inner ear disorders, in which case it is termed Meniere syndrome. The symptom triad may be a final common pathway of many different inner ear insults.",
"   </p>",
"   <p>",
"    This topic will present an overview of the diagnosis and treatment of Meniere disease. More detailed topics addressing the differential diagnosis of vertigo, tinnitus, and hearing loss are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=see_link\">",
"     \"Sudden sensorineural hearing loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meniere disease can begin at any age but patients typically present with symptoms between the ages of 20 and 40. Meniere syndrome in children is most often associated with congenital malformations of the inner ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise incidence of Meniere disease is difficult to determine because of nonstandard criteria for diagnosis, but the reported incidence ranges from 10 to 150 per 100,000 persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/4\">",
"     4",
"    </a>",
"    ]. Bilateral disease occurs in 10 to 50 percent of patients, with most reports quoting a 25 to 35 percent risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meniere disease is associated with endolymphatic hydrops with distortion and distention of the membranous, endolymph-containing portions of the labyrinthine system. Although most patients have no identifiable other underlying otologic disease, multiple potential causes of endolymphatic hydrops have been proposed (",
"    <a class=\"graphic graphic_table graphicRef50362 \" href=\"mobipreview.htm?28/49/29467\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is unclear why excess fluid builds up in the endolymphatic spaces of the inner ear. Several theories have been proposed, but all remain unproven. Lack of a single etiologic theory for Meniere disease may reflect underlying clinical and genetic heterogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed etiologies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blockage at the endolymphatic sac or duct &mdash; One popular theory postulates an abnormality in the resorption of endolymph at the endolymphatic sac. Endolymphatic hydrops has been experimentally induced in guinea pigs by blocking the entrance to the endolymphatic sac [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypoplasia of the vestibular aqueduct [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An immunologic mechanism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A genetic predisposition &mdash; An autosomal dominant inheritance pattern has been reported, involving 8 to 15 percent of patients with Meniere disease in two studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Patients with a family history had an earlier age of onset and the manifestations were more severe in successive generations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/14\">",
"       14",
"      </a>",
"      ]. A specific gene marker has not been identified.",
"     </li>",
"     <li>",
"      A viral etiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/16\">",
"       16",
"      </a>",
"      ] &mdash; Although a viral etiology has been proposed, DNA for suspected viruses (herpes simplex, varicella zoster, and cytomegalovirus) has not been detected in endolymphatic samples taken at surgery for patients with Meniere disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A vascular etiology &mdash; Migraine occurs more commonly in patients with Meniere disease than in the general population, leading to the postulation of a common vascular pathophysiology for the two disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism responsible for symptoms of Meniere disease is also unknown. While endolymphatic hydrops is present in all patients with Meniere disease, not all patients with endolymphatic hydrops have symptoms.",
"   </p>",
"   <p>",
"    The \"rupture theory\", elaborated 40 to 50 years ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], proposes that rupture of the dilated endolymphatic sac allows potassium-rich endolymph into the perilymphatic space. The resulting biochemical gradient depolarizes the cochlear and vestibular hair cells, resulting in acute loss of function. Once pressure between the endolymphatic and perilymphatic space is equalized, the membrane rupture can seal over. Ion \"pumps\" restore the normal gradient and hair cell function. Repeated ionic insults eventually lead to degeneration of the hair cells. Cytologic changes in hair cells with potassium ion intoxication have been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the rupture theory has been called into question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Meniere disease include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic vertigo (a true spinning sensation that has an onset and an offset)",
"     </li>",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Tinnitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Meniere disease is diagnosed only if patients complain of both episodic vertigo and sensorineural hearing loss. Aural fullness and nausea may be seen in conjunction with these symptoms. Affected patients tend to cycle from active symptoms to prolonged remissions. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Vertigo is characteristically rotatory spinning or a rocking sensation and may be associated with nausea and vomiting, and persists from 20 minutes to 24 hours duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/24\">",
"     24",
"    </a>",
"    ]. Additional sensations of disequilibrium or other patterns of dizziness are seen in about 15 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hearing loss is sensorineural, usually fluctuating, and often initially affects the lower frequencies. Hearing loss progresses over time, and often results in permanent hearing loss at all frequencies in the affected ear over an 8 to 10 year period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Downward fluctuations in hearing are typically associated with intense aural fullness or pressure in the ear or the side of the head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tinnitus is characteristically low pitch (like listening to a seashell or machinery) and may be associated with auditory distortion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course of Meniere disease varies among individuals. Some patients have marked hearing fluctuation and progressive hearing loss with infrequent vestibular symptoms; some have severe and frequent vertigo with only mild auditory symptoms; and some manifest both auditory and vestibular symptoms in equal measure. Approximately two-thirds of patients experience vertigo attacks in clusters, while one-third have sporadic attacks. The frequency of vertigo episodes may decline over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presumed diagnosis of endolymphatic hydrops is based upon clinical symptoms. There is no specific diagnostic test for Meniere disease and a definitive diagnosis can only be made postmortem.",
"   </p>",
"   <p>",
"    The clinical diagnosis in most patients is based upon the history, neurotologic evaluation, and clinical response to medical management. Patients usually have some variable auditory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vestibular symptoms for three to five years before they meet the diagnostic criteria for Meniere disease.",
"   </p>",
"   <p>",
"    Diagnostic criteria proposed by the American Academy of Otolaryngology and Head and Neck Surgery (AAO-HNS) stipulate that a \"definite\" diagnosis of Meniere disease requires the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two spontaneous episodes of rotational vertigo lasting at least 20 minutes",
"     </li>",
"     <li>",
"      Audiometric confirmation of sensorineural hearing loss",
"     </li>",
"     <li>",
"      Tinnitus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a perception of aural fullness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further investigation is also required to rule out other disorders in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audiometry should be performed in all patients with suspected Meniere disease. The most common audiometric pattern in early Meniere disease is a low frequency or combined low and high frequency sensory loss with normal hearing in the mid frequencies. Over time the hearing loss \"flattens out.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vestibular testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular testing may be normal early in the course, but will eventually be abnormal on the affected side. Testing is primarily useful in determining candidacy for interventional treatments or identifying possible bilateral disease.",
"   </p>",
"   <p>",
"    A standard vestibular evaluation includes electronystagmography (ENG), rotary chair testing, and computerized dynamic posturography. With progression of Meniere disease, both the ENG and rotary chair test should show evidence of declining peripheral vestibular function in the affected ear. The ENG (particularly the caloric test, in which the ear canals are irrigated with warm and cool water to stimulate the inner ear) is more sensitive for inner balance dysfunction, but the rotary chair test is more specific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood testing includes a search for suspected comorbid conditions (",
"    <a class=\"graphic graphic_table graphicRef66900 \" href=\"mobipreview.htm?1/6/1131\">",
"     table 2",
"    </a>",
"    ) and an RPR test for syphilis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tests for antibodies against inner ear antigens have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], but are not considered to be clinically useful and are not part of a routine evaluation for Meniere disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) can identify features that support a diagnosis of Meniere disease, but the findings are not diagnostic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/30\">",
"     30",
"    </a>",
"    ]. Nevertheless, MRI is usually indicated to rule out central nervous system (CNS) lesions that can mimic Meniere disease, including CNS tumors, aneurysms, or stenosis of the posterior circulation, Arnold-Chiari malformations, and findings suggesting multiple sclerosis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tests for endolymphatic hydrops",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific tests for endolymphatic hydrops include glycerine, urea, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    \"stress\" tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/31\">",
"     31",
"    </a>",
"    ], and electrocochleography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/32\">",
"     32",
"    </a>",
"    ]. These tests have low sensitivity and specificity and their role in the diagnosis and management of Meniere disease is controversial.",
"   </p>",
"   <p>",
"    The vestibular evoked myogenic potential (VEMP) is a newer test that shows promise for diagnosis and monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/33\">",
"     33",
"    </a>",
"    ]. Cervical VEMP (cVEMP) is an inhibitory sacculocollic reflex test that shows characteristic changes in symptomatic ears of Meniere patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/33\">",
"     33",
"    </a>",
"    ], and may detect early saccular hydrops before the onset of classic Meniere symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/34\">",
"     34",
"    </a>",
"    ]. Ocular VEMP (oVEMP) engages both utricular and saccular afferent nerve fibers and may also be useful in assessment of Meniere patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition to diagnosis, VEMP may be useful for monitoring patients for disease progression, and to identify the active ear in patients with bilateral disease. VEMP is an emerging technology that has not yet been standardized or fully validated clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that need to be considered when Meniere disease is suspected include (",
"    <a class=\"graphic graphic_table graphicRef63235 \" href=\"mobipreview.htm?39/16/40203\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vestibular schwannoma &mdash; Patients with vestibular schwannoma (acoustic neuroma) typically present with progressive asymmetric hearing loss but can sometimes have fluctuating hearing loss. Such patients rarely have true vertigo but may complain of imbalance. Occasional patients will have tinnitus and imbalance with normal hearing. Auditory brainstem response (auditory evoked response) testing and MRI in patients with vestibular schwannoma show abnormalities indicating compression of the eighth nerve complex. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"       \"Vestibular schwannoma (acoustic neuroma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple sclerosis &mdash; Multiple sclerosis (MS) can present with symptoms identical to those of Meniere disease. However, the observed nystagmus during an attack of MS is typically more severe and longer lasting, and the patients may have other neurologic complaints. Central abnormalities are seen on electronystagmogram testing (which is typically normal in early Meniere disease). White matter lesions may be seen on MRI and cerebrospinal fluid abnormalities may be detected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"       \"Diagnosis of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transient ischemic attack &mdash; Transient ischemic attacks (TIAs) are typically of shorter duration than Meniere attacks. In addition, patients with TIAs rarely experience simultaneous vestibular and cochlear symptoms, and TIAs do not cause persistent tinnitus or objective hearing loss. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=see_link\">",
"       \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Migraine &mdash; Migraine-associated vertigo is an important consideration, especially those with a history of migraine headache and in young patients with new onset of episodic vertigo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/36\">",
"       36",
"      </a>",
"      ]. The prevalence of migrainous vertigo is approximately 3 to 5 percent in the general population, far higher than the 0.2 percent prevalence of Meniere disease in the US population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/37\">",
"       37",
"      </a>",
"      ]. Migraine must always be considered as an alternative or confounding illness.",
"      <br/>",
"      <br/>",
"      Headache is usually present with migrainous vertigo, either during the episode or afterwards (when vertigo or tinnitus is a migraine aura). Migrainous vertigo is often accompanied by photophobia or phonophobia, symptoms not seen in vertigo episodes associated with Meniere disease. Diagnostic criteria include episodic vestibular symptoms, and at least two migraine symptoms (migrainous headache, photophobia, phonophobia, or visual or other aura) occurring during at least two vertiginous episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15496?source=see_link\">",
"       \"Migrainous vertigo\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Successful treatment with triptans during an attack is generally diagnostic, although migrainous vertigo is less responsive than headaches. A decrease in the frequency of events with migraine prophylaxis supports the diagnosis of migrainous vertigo. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &mdash; Diabetes and thyroid disease can sometimes cause symptoms that have some overlap with Meniere disease. Hearing complaints",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tinnitus are usually bilateral in these conditions and the patients often have chronic imbalance instead of attacks of true vertigo. Similar symptoms may occur in patients with severe anemia. Appropriate testing can diagnose these conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cogan's syndrome is a chronic inflammatory condition that occurs most commonly in young adults and can include vestibuloauditory symptoms that are similar to Meniere disease. The diagnosis is typically raised by the constellation of symptoms associated with Cogan's syndrome, including eye disease and systemic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12968?source=see_link\">",
"     \"Cogan&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meniere disease should be considered a chronic condition; treatment may successfully relieve symptoms but does not address the underlying abnormal pathophysiology.",
"   </p>",
"   <p>",
"    The goals of treatment are to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce the frequency and severity of vertigo attacks",
"     </li>",
"     <li>",
"      Reduce or eliminate hearing loss and tinnitus associated with attacks",
"     </li>",
"     <li>",
"      Alleviate chronic symptoms (tinnitus and balance issues)",
"     </li>",
"     <li>",
"      Minimize disability",
"     </li>",
"     <li>",
"      Prevent disease progression, particularly hearing loss and imbalance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient education is an important part of conservative management, and includes outlining an explanation of the disease, expectations for response, and treatment options. Up to 90 percent of patients with Meniere disease are able to maintain normal daily activities with medical management.",
"   </p>",
"   <p>",
"    Determining the optimal treatment for Meniere disease is limited by the lack of randomized, controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8,39\">",
"     8,39",
"    </a>",
"    ]. In addition, drug therapy has been associated with a significant placebo effect, and the relapsing remitting nature of the disorder has made evaluation of various treatments difficult.",
"   </p>",
"   <p>",
"    Vertigo attacks can be controlled in 90 to 95 percent of patients by conservative medical treatment, although progressive hearing loss rarely responds to treatment. Patients with suspected Meniere disease should be referred at a relatively early stage to an",
"    <span class=\"nowrap\">",
"     otologist/otolaryngologist.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONINTERVENTIONAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninterventional treatment for Meniere disease includes lifestyle adjustments, medical therapies, and rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lifestyle adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Meniere disease are more vulnerable to dietary and environmental factors that can impact hearing and balance. Triggers for Meniere disease may include high salt intake, caffeine, alcohol, nicotine, stress, monosodium glutamate (MSG), and allergies. Avoidance for patients with identified triggers may alleviate or ameliorate symptoms.",
"   </p>",
"   <p>",
"    Salt restriction is commonly recommended as part of initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], although data supporting its efficacy are not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ]. An appropriate salt-restricted diet will have approximately 2 to 3 g of sodium per day. The daily sodium intake should be evenly spread across meals to avoid a large bolus at any time. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"     \"Patient information: Low sodium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caffeine and nicotine are vasoconstrictors that may reduce microvascular flow in the labyrinthine system. Alcohol also causes fluid and electrolyte shifts that can stress a fragile ear. Limiting caffeine to one caffeinated beverage (coffee, tea, or cola) daily and limiting alcohol to one drink daily is typically recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Medical management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Acute episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute episodes of vertigo should be managed with vestibular suppressants and antiemetics (",
"    <a class=\"graphic graphic_table graphicRef68052 \" href=\"mobipreview.htm?25/16/25868\">",
"     table 4",
"    </a>",
"    ). Doses should be started low and increased to positive effect or side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link\">",
"     \"Treatment of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vestibular suppressants include benzodiazepines, that have the advantage of anxiolytic properties for short-term use, antihistamines (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    ), and anticholinergics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     Promethazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    may be used for the acute treatment of severe nausea and vomiting and are available in suppository form.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    has been administered sublingually in \"off-label\" usage. Although this has not been studied in clinical trials, otologists have found that a dose of 0.5 to 1 mg administered up to four times daily may achieve relief of acute vertigo attacks.",
"   </p>",
"   <p>",
"    Rest and, if appropriate, volume repletion are important adjuvant therapies in the acute setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications have been used to treat Meniere disease (",
"    <a class=\"graphic graphic_table graphicRef81415 \" href=\"mobipreview.htm?20/25/20892\">",
"     table 5",
"    </a>",
"    ). Diuretics and as-needed vestibular",
"    <span class=\"nowrap\">",
"     suppressants/antiemetics",
"    </span>",
"    are typically used when diet alone does not adequately control the episodes. Combinations of these agents control episodes of vertigo in the majority of patients, although they have not been shown to affect hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diuretics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17059?source=see_link\">",
"     betahistine",
"    </a>",
"    have been thought to reduce the degree of endolymphatic hydrops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. Betahistine, a vasodilator available in Europe, is reported to act by improving microvascular circulation in the stria vascularis of the cochlea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/44\">",
"     44",
"    </a>",
"    ] or by inhibiting vestibular nuclei activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One review found that diuretics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17059?source=see_link\">",
"     betahistine",
"    </a>",
"    hydrochloride were the only drugs with demonstrated efficacy for long-term control of vertigo in double-blind trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/43\">",
"     43",
"    </a>",
"    ]. However, two subsequent systematic literature reviews found methodologic flaws in all trials, with no trials of either diuretics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/46\">",
"     46",
"    </a>",
"    ] or betahistine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/47\">",
"     47",
"    </a>",
"    ] being of sufficient quality to meet the review standard for use. In the absence of better data and the low risk of adverse effects, we suggest use of diuretics when diet alone does not adequately control episodes.",
"   </p>",
"   <p>",
"    Use of systemic glucocorticoid therapy for Meniere disease has been considered, based on the possible immunologic etiology, and the role of steroids in patients with sudden sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there are no randomized or prospective trials of oral glucocorticoids in patients with Meniere disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/48\">",
"     48",
"    </a>",
"    ]. Similarly, definitive studies are needed before immunosuppressive therapy with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/49\">",
"     49",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/50\">",
"     50",
"    </a>",
"    ] can be recommended.",
"   </p>",
"   <p>",
"    Patients have reported improvement with vitamin regimens, herbal remedies, and vasodilators. However, these treatments are not supported by evidence of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Meniere disease may be candidates for hearing aid use, vestibular rehabilitation therapy, or other types of rehabilitation. Vestibular rehabilitation uses exercise activities to maximize balance and central nervous system compensation for disequilibrium.",
"   </p>",
"   <p>",
"    Vestibular rehabilitation has been used primarily in patients whose vertigo responded to medical or surgical treatment, but who had residual disequilibrium. In a series of 26 patients who had responded to treatment for vertigo prior to study inclusion, an eight week vestibular therapy program in a tertiary referral center demonstrated a composite 25 percent improvement on four tests of disequilibrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/51\">",
"     51",
"    </a>",
"    ]. Vestibular rehabilitation may also be considered for untreated patients with Meniere disease who experience significant balance and disequilibrium symptoms between acute spells of vertigo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there is no evidence of a reduction in the frequency or severity of vertigo attacks.",
"   </p>",
"   <p>",
"    Hearing aids should be considered for patients with significant binaural hearing loss, but frustration due to hearing fluctuation leads to poor patient compliance in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTERVENTIONAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients have intractable or progressive, unremitting symptoms that significantly impair their quality of life, despite medical therapy. These individuals are candidates for invasive treatments.",
"   </p>",
"   <p>",
"    The American Academy of Otolaryngology-Head and Neck Foundation (AAO-HNS) has set forth criteria for Meniere disease disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild &mdash; intermittent or continuous",
"      <span class=\"nowrap\">",
"       dizziness/unsteadiness",
"      </span>",
"      that precludes working in a hazardous environment.",
"     </li>",
"     <li>",
"      Moderate &mdash; intermittent or continuous dizziness that results in a sedentary occupation.",
"     </li>",
"     <li>",
"      Severe disability &mdash; symptoms so severe as to exclude gainful employment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A self-assessment tool developed by the AAO-HNS, the Meniere Disease Functional Level Scale (",
"    <a class=\"graphic graphic_table graphicRef72837 \" href=\"mobipreview.htm?1/15/1276\">",
"     table 6",
"    </a>",
"    ), is useful in identifying patients who are candidates for interventional treatment to control vertigo, and in assessing efficacy of therapy.",
"   </p>",
"   <p>",
"    Interventional treatments for Meniere syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Destructive therapies, which act to reduce or eliminate signals from the affected labyrinthine system to the brain",
"     </li>",
"     <li>",
"      Nondestructive surgical treatments, whose mechanisms of action are unknown, but perhaps reduce the accumulation of fluid in the endolymphatic spaces, or otherwise alter fluid and electrolyte physiology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no agreement on which procedures are first line therapy. The degree of labyrinthine function and the level of hearing determine the best initial interventional treatment for an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Destructive procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Destructive procedures for the treatment of Meniere disease include intratympanic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    injection, surgical labyrinthectomy, and vestibular nerve section. In general, destructive techniques are better suited to patients who have failed medical therapy and who have unilateral disease. However, in cases of severe bilateral disease or intractable vertigo, labyrinthine ablation must still be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Intratympanic gentamicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglycosides are toxic to the sensory neuroepithelium of the inner ear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    delivered into the middle ear space, by injection or cannula, allows the drug to locally penetrate the labyrinth through the round window membrane and destroy hair cells in the semicircular canals, ablating labyrinthine function on the treated side without adverse systemic effects.",
"   </p>",
"   <p>",
"    Multiple cohort studies have found that applications of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    control vertiginous symptoms of Meniere disease in 80 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. One systematic review including two randomized trials of patients with Meniere disease found that intratympanic gentamicin was effective in reducing symptoms of vertigo, compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/56\">",
"     56",
"    </a>",
"    ]. However, this therapy does not affect hydrops and the associated fullness, hearing fluctuations, and sensory loss. Treatment is associated with a moderate risk of sensorineural loss (up to 30 percent of patients) that is irreversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A newer technique uses a minimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (0.5 to 0.75 mL of a 40",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    solution of gentamicin) injected into the middle ear, with the intent to impact vestibular function without affecting cochlear function. In one study, one transtympanic gentamicin injection resulted in good control of vertigo in 76 percent of patients followed for four or more years, with minimal cochlear loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/58\">",
"     58",
"    </a>",
"    ]. A second injection was required in 15 to 20 percent of patients. An open randomized trial compared low-dose intratympanic gentamicin (2.0 mL of a 40.0",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    solution of gentamicin, maximum of two injections) with intratympanic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    three injections over seven days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/59\">",
"     59",
"    </a>",
"    ]. Complete and substantial vertigo control (81.0 and 12.5 percent, respectively) was greater in the gentamicin group compared with the dexamethasone group (43 and 18 percent, respectively). Significant hearing loss (&gt;10 dB) occurred in 4 of 32 patients in the gentamicin group.",
"   </p>",
"   <p>",
"    There is little consensus of the optimal protocol for intratympanic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    administration. One meta-analysis found that titrating repeated gentamicin doses until a vestibular response is achieved is superior to other treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/60\">",
"     60",
"    </a>",
"    ], while another meta-analysis found no difference in effectiveness for fixed dose or titration regimens, but noted significant quality issues in all trials evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/61\">",
"     61",
"    </a>",
"    ]. Intratympanic gentamicin is now widely accepted as the treatment of choice for most patients with intractable vertigo who have failed diet and diuretic therapy and have significant hearing loss in the affected ear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Labyrinthectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical destruction of the bony and membranous labyrinth by removal of all of the neuroepithelium from the treated side relieves vertigo in virtually all patients but also causes irreversible hearing loss in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, it is only indicated in individuals with intractable symptoms despite medical therapy who already have poor or complete hearing loss on the affected side.",
"   </p>",
"   <p>",
"    The concern of many physicians is that patients may have subclinical disease in the opposite ear that will ultimately progress and cause total deafness. We do not believe that treatment should be withheld in patients with disabling vertigo or drop attacks, for a potential and unpredictable future event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Vestibular neurectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular neurectomy involves surgical lysis of the vestibular nerve bundle as it enters the internal auditory canal. It relieves vertigo in 90 to 95 percent of patients and is associated with a low risk (10 to 20 percent) of sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, vestibular neurectomy requires general anesthesia with craniotomy and overnight monitoring in an intensive care unit, and is associated with significantly more morbidity than labyrinthectomy. Up to 25 percent of patients experience postoperative headache, and 7 percent have a leak of cerebrospinal fluid. In one series, hearing was preserved in 82 percent of patients undergoing this procedure, although the gradual progression of deafness due to Meniere was not altered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/62\">",
"     62",
"    </a>",
"    ]. Since the widespread adoption of intratympanic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    treatment for patients who fail non-invasive therapies, vestibular neurectomy has become a very infrequent treatment choice. It is reserved for those patients who have failed non-invasive therapies and who still have a level of hearing in the affected ear that they are unwilling to risk to intratympanic gentamicin. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Intratympanic gentamicin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nondestructive procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nondestructive surgical procedures include endolymphatic sac procedures (enhancement or shunting or both) and sacculotomy. These procedures are associated with a low risk of sensorineural hearing loss and are commonly performed for Meniere disease in patients with intact hearing, despite concerns that effectiveness may be due to placebo effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These procedures expose the endolymphatic sac and duct, with the aim to improve drainage of endolymph. However, anatomic studies of the endolymphatic sac indicate that such drainage is not plausible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Control of vertigo has been reported in 75 to 80 percent of patients in uncontrolled case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/65-69\">",
"     65-69",
"    </a>",
"    ]. Symptomatic improvement in hearing and tinnitus have also been reported with apparent long-term maintenance of benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Installation of steroids into the endolymphatic sac following drainage, in a controlled trial, did not affect the response rate for relief of vertigo symptoms but increased the percent of patients who had some hearing improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only trial of endolymphatic shunt surgery that used sham surgery as a control concluded no difference in effectiveness for the sham or interventional procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/71\">",
"     71",
"    </a>",
"    ]. These results have been called into question with reanalysis that challenged both study design and statistical analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Intratympanic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible immunologic basis for Meniere disease and use of intratympanic glucocorticoids in treatment of sudden sensorineural hearing loss and in tinnitus has led to studies of intratympanic steroids in patients with intractable Meniere disease that have found some benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 22 patients with Meniere disease, patients randomly assigned to intratympanic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/ml",
"      </span>",
"      daily for five consecutive days) had improvement in symptoms and functional scores compared to those assigned to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective cohort study of 21 patients, complete relief of vertigo was maintained in 9 patients (43 percent) at six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/74\">",
"       74",
"      </a>",
"      ]. The complication rate was low, although repeated injection was often necessary and the efficacy of the injection appeared to decrease over time.",
"     </li>",
"     <li>",
"      A retrospective review of over 120 patients with two year follow-up showed that vertigo symptoms could be controlled to a level that obviated need for destructive therapy in approximately 90 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial comparing intratympanic low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      and intratympanic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , control of vertigo was significantly greater for the gentamicin group, but 43 percent of patients in the dexamethasone group did achieve complete vertigo control with no loss and even slight improvement in hearing for those whose vertigo improved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies have shown that vertigo symptoms may improve, without change in hearing or tinnitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ]. Optimal regimens for intratympanic glucocorticoids have not been developed, and further studies are indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Positive pressure pulse generator (Meniett)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure applied to the middle ear may improve fluid exchange in the inner ear. Overpressure treatment, in which a device (Meniett&reg; pulse generator) applies pulses of pressure to the middle ear via a ventilation tube, is an option for patients who fail medical therapy or as an adjunct to medical therapy in patients with functional level 3 or greater (",
"    <a class=\"graphic graphic_table graphicRef72837 \" href=\"mobipreview.htm?1/15/1276\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several randomized double-blind placebo-controlled studies have shown short-term efficacy and safety of overpressure pulsing in the treatment of refractory Meniere disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Long-term efficacy has also been demonstrated in two small studies with 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/79\">",
"     79",
"    </a>",
"    ] and 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/80\">",
"     80",
"    </a>",
"    ] of patients maintaining improvement in vertigo symptoms at two-year follow-up. Maintenance of a patent tympanostomy tube is required for overpressure treatment. The device is expensive, and does not improve subjective hearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/10/40097?source=see_link\">",
"       \"Patient information: Meniere disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=see_link\">",
"       \"Patient information: Dizziness and vertigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meniere disease is a clinical diagnosis, associated with hearing loss, episodic vertigo, and tinnitus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Meniere disease have endolymphatic hydrops in the labyrinthine system of the affected ear. The etiology is unknown, but may be related to anatomic, immunologic, genetic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sensorineural hearing loss is fluctuating and progressive. Vertigo episodes last from 20 minutes to 24 hours and typically occur in clusters. Aural fullness and nausea may be associated with other symptoms. Symptoms are cyclical and prolonged periods of remission are typical. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meniere disease is a clinical diagnosis. Although not diagnostic, patients should undergo audiometry, vestibular testing, and MRI to rule out other causes of symptoms (",
"      <a class=\"graphic graphic_table graphicRef66900 \" href=\"mobipreview.htm?1/6/1131\">",
"       table 2",
"      </a>",
"      ). The vestibular evoked myogenic potential (VEMP) test may be useful for monitoring disease progression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meniere disease is a chronic condition; patients should be given reasonable expectations of treatment, which include symptom relief but not cure. Patients with suspected Meniere disease should be referred at a relatively early stage to an",
"      <span class=\"nowrap\">",
"       otologist/otolaryngologist.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Principles of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients limit intake of salt, caffeine, nicotine, and alcohol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Acute symptoms of vertigo should be managed with appropriate medication (",
"      <a class=\"graphic graphic_table graphicRef68052 \" href=\"mobipreview.htm?25/16/25868\">",
"       table 4",
"      </a>",
"      ). We suggest use of diuretics when diet alone does not adequately control episodes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Vestibular rehabilitation may help patients with residual disequilibrium, and hearing aids can improve hearing in compliant patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Noninterventional treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventional therapy may be indicated in the 5 to 10 percent of patients who have intractable vertigo symptoms that significantly impair quality of life despite aggressive medical management. The degree of labyrinthine function and level of hearing determine the best initial interventional treatment for an individual patient.",
"     </li>",
"     <li>",
"      Interventional techniques include destructive procedures (intratympanic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      , labyrinthectomy, and vestibular neurectomy) and nondestructive procedures. Endolymphatic sac surgery has been effective for patients with intact hearing in prospective series, although a placebo response has been implicated. Intratympanic glucocorticoids may improve vertigo symptoms, but await controlled trials. A positive-pressure pulse generator has demonstrated long-term effectiveness but requires a patent tympanostomy and is expensive. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Interventional treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/1\">",
"      Meniere P. Congestions cerebrales apoplectiformes. Gaz md Paris 1861; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/2\">",
"      Meyerhoff WL, Paparella MM, Shea D. M&eacute;ni&egrave;re's disease in children. Laryngoscope 1978; 88:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/3\">",
"      Jackler RK, Luxford WM, Brackmann DE, Monsell EM. Endolymphatic sac surgery in congenital malformations of the inner ear. Laryngoscope 1988; 98:698.",
"     </a>",
"    </li>",
"    <li>",
"     Schessel DA, Minor LB, Nedzelski J. Meniere's disease and other peripheral vestibular disorders. In: Otolaryngology Head and Neck Surgery, Cummings CW (Ed), Mosby, St. Louis 1998. p.2672.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/5\">",
"      Balkany TJ, Sires B, Arenberg IK. Bilateral aspects of Meniere's disease: an underestimated clinical entity. Otolaryngol Clin North Am 1980; 13:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/6\">",
"      Enander A, Stahle J. Hearing in Meni&egrave;re's disease. A study of pure-tone audiograms in 334 patients. Acta Otolaryngol 1967; 64:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/7\">",
"      Mizukoshi K, Ino H, Ishikawa K, et al. Epidemiological survey of definite cases of Meniere's disease collected by the seventeen members of the Meniere's Disease Research Committee of Japan in 1975--1976. Adv Otorhinolaryngol 1979; 25:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/8\">",
"      Coelho DH, Lalwani AK. Medical management of M&eacute;ni&egrave;re's disease. Laryngoscope 2008; 118:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/9\">",
"      Kimura RS. Experimental blockage of the endolymphatic duct and sac and its effect on the inner ear of the guinea pig. A study on endolymphatic hydrops. Ann Otol Rhinol Laryngol 1967; 76:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/10\">",
"      Yamamoto E, Mizukami C. Development of the vestibular aqueduct in Meni&egrave;re's disease. Acta Otolaryngol Suppl 1993; 504:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/11\">",
"      Alleman AM, Dornhoffer JL, Arenberg IK, Walker PD. Demonstration of autoantibodies to the endolymphatic sac in Meniere's disease. Laryngoscope 1997; 107:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/12\">",
"      Evans KL, Baldwin DL, Bainbridge D, Morrison AW. Immune status in patients with Meni&egrave;re's disease. Arch Otorhinolaryngol 1988; 245:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/13\">",
"      Brookes GB. Circulating immune complexes in Meniere's disease. Arch Otolaryngol Head Neck Surg 1986; 112:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/14\">",
"      Morrison AW. Anticipation in Meni&egrave;re's disease. J Laryngol Otol 1995; 109:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/15\">",
"      Klockars T, Kentala E. Inheritance of Meniere's disease in the Finnish population. Arch Otolaryngol Head Neck Surg 2007; 133:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/16\">",
"      Calenoff E, Zhao JC, Derlacki EL, et al. Patients with Meni&eacute;re's disease possess IgE reacting with herpes family viruses. Arch Otolaryngol Head Neck Surg 1995; 121:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/17\">",
"      Welling DB, Daniels RL, Brainard J, et al. Detection of viral DNA in endolymphatic sac tissue from Meni&egrave;re's disease patients. Am J Otol 1994; 15:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/18\">",
"      Parker W. Meni&egrave;re's disease. Etiologic considerations. Arch Otolaryngol Head Neck Surg 1995; 121:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/19\">",
"      Radtke A, Lempert T, Gresty MA, et al. Migraine and M&eacute;ni&egrave;re's disease: is there a link? Neurology 2002; 59:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/20\">",
"      LAWRENCE M, MCCABE BF. Inner-ear mechanics and deafness. Special consideration of Meniere's syndrome. J Am Med Assoc 1959; 171:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/21\">",
"      SCHUKNECHT H. MENIERE'S DISEASE. J Otolaryngol Soc Aust 1963; 30:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/22\">",
"      Duvall AJ 3rd, Santi PA, Hukee MJ. Cochlear fluid balance. A clinical/research overview. Ann Otol Rhinol Laryngol 1980; 89:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/23\">",
"      Brown DH, McClure JA, Downar-Zapolski Z. The membrane rupture theory of Meni&egrave;re's disease--is it valid? Laryngoscope 1988; 98:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/24\">",
"      Saeed SR. Fortnightly review. Diagnosis and treatment of M&eacute;ni&egrave;re's disease. BMJ 1998; 316:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/25\">",
"      Perez-Garrigues H, Lopez-Escamez JA, Perez P, et al. Time course of episodes of definitive vertigo in Meniere's disease. Arch Otolaryngol Head Neck Surg 2008; 134:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/26\">",
"      Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meni&egrave;re's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/27\">",
"      Gottschlich S, Billings PB, Keithley EM, et al. Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Meni&egrave;re's disease. Laryngoscope 1995; 105:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/28\">",
"      Bloch DB, San Martin JE, Rauch SD, et al. Serum antibodies to heat shock protein 70 in sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 1995; 121:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/29\">",
"      Shin SO, Billings PB, Keithley EM, Harris JP. Comparison of anti-heat shock protein 70 (anti-hsp70) and anti-68-kDa inner ear protein in the sera of patients with Meniere's disease. Laryngoscope 1997; 107:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/30\">",
"      Lorenzi MC, Bento RF, Daniel MM, Leite CC. Magnetic resonance imaging of the temporal bone in patients with M&eacute;ni&egrave;re's disease. Acta Otolaryngol 2000; 120:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/31\">",
"      Yen PT, Lin CC, Huang TS. A preliminary report on the correlation of vestibular Meni&eacute;re's disease with electrocochleography and glycerol test. Acta Otolaryngol Suppl 1995; 520 Pt 2:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/32\">",
"      Conlon BJ, Gibson WP. Electrocochleography in the diagnosis of Meniere's disease. Acta Otolaryngol 2000; 120:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/33\">",
"      Rauch SD, Zhou G, Kujawa SG, et al. Vestibular evoked myogenic potentials show altered tuning in patients with M&eacute;ni&egrave;re's disease. Otol Neurotol 2004; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/34\">",
"      Lin MY, Timmer FC, Oriel BS, et al. Vestibular evoked myogenic potentials (VEMP) can detect asymptomatic saccular hydrops. Laryngoscope 2006; 116:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/35\">",
"      Taylor RL, Wijewardene AA, Gibson WP, et al. The vestibular evoked-potential profile of M&eacute;ni&egrave;re's disease. Clin Neurophysiol 2011; 122:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/36\">",
"      Boyev KP. Meniere's disease or migraine? The clinical significance of fluctuating hearing loss with vertigo. Arch Otolaryngol Head Neck Surg 2005; 131:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/37\">",
"      Wladislavosky-Waserman P, Facer GW, Mokri B, Kurland LT. Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980. Laryngoscope 1984; 94:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/38\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/39\">",
"      Thorp MA, Shehab ZP, Bance ML, Rutka JA. Does evidence-based medicine exist in the treatment of Meni&egrave;re's disease? A critical review of the last decade of publications. Clin Otolaryngol Allied Sci 2000; 25:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/40\">",
"      Santos PM, Hall RA, Snyder JM, et al. Diuretic and diet effect on Meni&egrave;re's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines. Otolaryngol Head Neck Surg 1993; 109:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/41\">",
"      Boles R, Rice DH, Hybels R, Work WP. Conservative management of M&eacute;ni&eacute;re's disease: Furstenberg regimen revisited. Ann Otol Rhinol Laryngol 1975; 84:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/42\">",
"      Kinney SE, Sandridge SA, Newman CW. Long-term effects of M&eacute;ni&egrave;re's disease on hearing and quality of life. Am J Otol 1997; 18:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/43\">",
"      Claes J, Van de Heyning PH. A review of medical treatment for M&eacute;ni&egrave;re's disease. Acta Otolaryngol Suppl 2000; 544:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/44\">",
"      Martinez DM. The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Otolaryngol Suppl 1972; 305:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/45\">",
"      Timmerman H. Pharmacotherapy of vertigo: any news to be expected? Acta Otolaryngol Suppl 1994; 513:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/46\">",
"      Thirlwall AS, Kundu S. Diuretics for M&eacute;ni&egrave;re's disease or syndrome. Cochrane Database Syst Rev 2006; :CD003599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/47\">",
"      James AL, Burton MJ. Betahistine for Meni&egrave;re's disease or syndrome. Cochrane Database Syst Rev 2001; :CD001873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/48\">",
"      Cope D, Bova R. Steroids in otolaryngology. Laryngoscope 2008; 118:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/49\">",
"      Kilpatrick JK, Sismanis A, Spencer RF, Wise CM. Low-dose oral methotrexate management of patients with bilateral M&eacute;ni&egrave;re's disease. Ear Nose Throat J 2000; 79:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/50\">",
"      Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol 2001; 22:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/51\">",
"      Gottshall KR, Hoffer ME, Moore RJ, Balough BJ. The role of vestibular rehabilitation in the treatment of Meniere's disease. Otolaryngol Head Neck Surg 2005; 133:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/52\">",
"      Nedzelski JM, Schessel DA, Bryce GE, Pfleiderer AG. Chemical labyrinthectomy: local application of gentamicin for the treatment of unilateral Meni&egrave;re's disease. Am J Otol 1992; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/53\">",
"      Quaranta A, Aloisi A, De Benedittis G, Scaringi A. Intratympanic therapy for M&eacute;ni&egrave;re's disease. High-concentration gentamicin with round-window protection. Ann N Y Acad Sci 1999; 884:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/54\">",
"      Perez N, Mart&iacute;n E, Garc&iacute;a-Tapia R. Intratympanic gentamicin for intractable Meniere's disease. Laryngoscope 2003; 113:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/55\">",
"      Boleas-Aguirre MS, S&aacute;nchez-Ferrandiz N, Guill&eacute;n-Grima F, Perez N. Long-term disability of class A patients with M&eacute;ni&egrave;re's disease after treatment with intratympanic gentamicin. Laryngoscope 2007; 117:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/56\">",
"      Pullens B, van Benthem PP. Intratympanic gentamicin for M&eacute;ni&egrave;re's disease or syndrome. Cochrane Database Syst Rev 2011; :CD008234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/57\">",
"      Blakley BW. Update on intratympanic gentamicin for Meniere's disease. Laryngoscope 2000; 110:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/58\">",
"      Harner SG, Driscoll CL, Facer GW, et al. Long-term follow-up of transtympanic gentamicin for M&eacute;ni&egrave;re's syndrome. Otol Neurotol 2001; 22:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/59\">",
"      Casani AP, Piaggi P, Cerchiai N, et al. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg 2012; 146:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/60\">",
"      Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for M&eacute;ni&egrave;re's disease: a meta-analysis. Otol Neurotol 2004; 25:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/61\">",
"      Cohen-Kerem R, Kisilevsky V, Einarson TR, et al. Intratympanic gentamicin for Meni&egrave;re's disease: a meta-analysis. Laryngoscope 2004; 114:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/62\">",
"      Gacek RR, Gacek MR. Comparison of labyrinthectomy and vestibular neurectomy in the control of vertigo. Laryngoscope 1996; 106:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/63\">",
"      Kim HH, Wiet RJ, Battista RA. Trends in the diagnosis and the management of Meniere's disease: results of a survey. Otolaryngol Head Neck Surg 2005; 132:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/64\">",
"      Friberg U, Jansson B, Rask-Andersen H, Bagger-Sj&ouml;b&auml;ck D. Variations in surgical anatomy of the endolymphatic sac. Arch Otolaryngol Head Neck Surg 1988; 114:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/65\">",
"      Moffat DA. Endolymphatic sac surgery: analysis of 100 operations. Clin Otolaryngol Allied Sci 1994; 19:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/66\">",
"      Telischi FF, Luxford WM. Long-term efficacy of endolymphatic sac surgery for vertigo in Meni&egrave;re's disease. Otolaryngol Head Neck Surg 1993; 109:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/67\">",
"      Brinson GM, Chen DA, Arriaga MA. Endolymphatic mastoid shunt versus endolymphatic sac decompression for M&eacute;ni&egrave;re's disease. Otolaryngol Head Neck Surg 2007; 136:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/68\">",
"      Kitahara T, Kubo T, Okumura S, Kitahara M. Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: a long-term follow-up and randomized controlled study. Laryngoscope 2008; 118:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/69\">",
"      Wetmore SJ. Endolymphatic sac surgery for M&eacute;ni&egrave;re's disease: long-term results after primary and revision surgery. Arch Otolaryngol Head Neck Surg 2008; 134:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/70\">",
"      Ostrowski VB, Kartush JM. Endolymphatic sac-vein decompression for intractable Meniere's disease: long term treatment results. Otolaryngol Head Neck Surg 2003; 128:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/71\">",
"      Thomsen J, Bretlau P, Tos M, Johnsen NJ. Placebo effect in surgery for M&eacute;ni&egrave;re's disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery. Arch Otolaryngol 1981; 107:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/72\">",
"      Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation of efficacy. Otolaryngol Head Neck Surg 2000; 122:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/73\">",
"      Phillips JS, Westerberg B. Intratympanic steroids for M&eacute;ni&egrave;re's disease or syndrome. Cochrane Database Syst Rev 2011; :CD008514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/74\">",
"      Barrs DM, Keyser JS, Stallworth C, McElveen JT Jr. Intratympanic steroid injections for intractable M&eacute;ni&egrave;re's disease. Laryngoscope 2001; 111:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/75\">",
"      Boleas-Aguirre MS, Lin FR, Della Santina CC, et al. Longitudinal results with intratympanic dexamethasone in the treatment of M&eacute;ni&egrave;re's disease. Otol Neurotol 2008; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/76\">",
"      Thomsen J, Sass K, Odkvist L, Arlinger S. Local overpressure treatment reduces vestibular symptoms in patients with Meniere's disease: a clinical, randomized, multicenter, double-blind, placebo-controlled study. Otol Neurotol 2005; 26:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/77\">",
"      Gates GA, Green JD Jr, Tucci DL, Telian SA. The effects of transtympanic micropressure treatment in people with unilateral Meniere's disease. Arch Otolaryngol Head Neck Surg 2004; 130:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/78\">",
"      Odkvist LM, Arlinger S, Billermark E, et al. Effects of middle ear pressure changes on clinical symptoms in patients with M&eacute;ni&egrave;re's disease--a clinical multicentre placebo-controlled study. Acta Otolaryngol Suppl 2000; 543:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/79\">",
"      Gates GA, Verrall A, Green JD Jr, et al. Meniett clinical trial: long-term follow-up. Arch Otolaryngol Head Neck Surg 2006; 132:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32729/abstract/80\">",
"      Densert B, Sass K. Control of symptoms in patients with Meniere's disease using middle ear pressure applications: two years follow-up. Acta Otolaryngol 2001; 121:616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6859 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-9B4BA70C19-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32729=[""].join("\n");
var outline_f31_61_32729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Audiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vestibular testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tests for endolymphatic hydrops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRINCIPLES OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONINTERVENTIONAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lifestyle adjustments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Medical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Acute episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTERVENTIONAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Destructive procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Intratympanic gentamicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Labyrinthectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Vestibular neurectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nondestructive procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Surgical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Intratympanic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Positive pressure pulse generator (Meniett)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6859|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/49/29467\" title=\"table 1\">",
"      Causes of endolymphatic hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/6/1131\" title=\"table 2\">",
"      Causes Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/16/40203\" title=\"table 3\">",
"      Diff diagnosis Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/16/25868\" title=\"table 4\">",
"      Drugs for acute vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/25/20892\" title=\"table 5\">",
"      Meds for Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/15/1276\" title=\"table 6\">",
"      Funct level scale for Meniere disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12968?source=related_link\">",
"      Cogan&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15496?source=related_link\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/10/40097?source=related_link\">",
"      Patient information: Meniere disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=related_link\">",
"      Sudden sensorineural hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_61_32730="Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis";
var content_f31_61_32730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32730/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32730/contributors\">",
"     Kevin R Krull, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32730/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32730/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/61/32730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/61/32730/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/61/32730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in early childhood with symptoms of hyperactivity, impulsivity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inattention. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of the treatment and prognosis of ADHD in children. Other topics related to ADHD are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4954?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link\">",
"       \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34423?source=see_link\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32761?source=see_link\">",
"       \"Adult attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197690673\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for ADHD are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ). The evaluation and diagnosis of ADHD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007891978\">",
"    <span class=\"h2\">",
"     Care coordination",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD is a chronic condition and should be managed in a manner similar to other chronic conditions of childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition to regularly monitoring the effectiveness of therapeutic interventions, it is important for primary care clinicians to provide information to the family and child about ADHD, help the family set specific treatment goals, and offer information regarding local support groups if they are available (",
"    <a class=\"graphic graphic_table graphicRef60584 \" href=\"mobipreview.htm?26/42/27308\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27737?source=see_link\">",
"     \"Children with special health care needs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=see_link\">",
"     \"Support services for the care of chronically ill children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular communication between the parents and the teachers is important. This can occur through a daily report card or a weekly communication book.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130698002\">",
"    <span class=\"h2\">",
"     Involvement of patient and family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ADHD may involve behavioral interventions, medication, school-based interventions, or psychological interventions alone or in combination (see",
"    <a class=\"local\" href=\"#H484900\">",
"     'Treatment modalities'",
"    </a>",
"    below). Decisions regarding the choice of therapy should involve the patient and his or her parents. Together with the treating clinician, the patient and family must evaluate the risks and benefits of the various treatment options to determine the optimal treatment strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483677\">",
"    <span class=\"h2\">",
"     Target goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with ADHD centers upon the achievement of target outcomes that are realistic, achievable, and measurable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. Specific target outcomes may change over the course of treatment and should be determined in collaboration with the parents, child, and school personnel. Between three and six target outcomes are addressed at any given time. Progress can be monitored with a daily report card.",
"   </p>",
"   <p>",
"    Examples of target outcomes include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improved relationships with parents, teachers, siblings, or peers (eg, plays without fighting at recess)",
"     </li>",
"     <li>",
"      Improved academic performance (eg, completes academic assignments)",
"     </li>",
"     <li>",
"      Improved rule following (eg, does not talk back to the teacher)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1404650528\">",
"    <span class=\"h2\">",
"     Treatment of coexisting conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as one-third of children with ADHD have one or more coexisting conditions (eg, learning disabilities, oppositional defiant disorder, conduct disorder, anxiety disorder, mood disorders, tics, sleep disorders) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It is important to treat coexisting conditions concurrently with ADHD; treatment of coexisting conditions may influence the treatment for ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ]. Adjunctive behavioral and psychologic interventions may be necessary for managing the full spectrum of symptoms in children with ADHD and coexisting conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2162173\">",
"    <span class=\"h2\">",
"     Indications for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD in children 4 to 18 years of age without comorbid conditions can usually be managed by the primary care provider [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ]. Indications for referral to or consultation with a specialist (eg, developmental behavioral pediatrician, child neurologist, psychopharmacologist, child psychiatrist, clinical child psychologist) may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coexisting psychiatric conditions (eg, oppositional defiant disorder, conduct disorder, substance abuse, emotional problems) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H22#H22\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Coexisting disorders'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coexisting neurologic, or medical conditions (eg, seizures, tics, autism spectrum disorder, sleep disorder) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H13#H13\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lack of response to a controlled trial of stimulant therapy or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898721#H2007898721\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Dose titration'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268239\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment strategies for children with ADHD vary according to age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. The American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, the United Kingdom&rsquo;s National Institute for Health and Clinical Excellence, the Scottish Intercollegiate Guideline Network, and the European Network for Hyperkinetic Disorders, have developed guidelines or practice parameters for the evaluation and management of children with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2-4,11,12\">",
"     2-4,11,12",
"    </a>",
"    ]. The recommendations included in this topic review are consistent with the recommendations of these groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483772\">",
"    <span class=\"h2\">",
"     Preschool children",
"    </span>",
"    &nbsp;&mdash;&nbsp;For preschool children (age 4 through 5 years) who meet the diagnostic criteria for ADHD (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ), we recommend behavior therapy rather than medication as the initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. Behavior therapy can be administered by the parents or teachers. (See",
"    <a class=\"local\" href=\"#H966764713\">",
"     'Behavioral interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The addition of medication to behavior therapy may be indicated if target behaviors do not improve with behavioral therapy and the child&rsquo;s function continues to be impaired. Examples of situations in which medication may be warranted for preschool children include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Expulsion (or threatened expulsion) from preschool or daycare",
"     </li>",
"     <li>",
"      Significant risk of injury to other children or caregivers",
"     </li>",
"     <li>",
"      Strong family history of ADHD",
"     </li>",
"     <li>",
"      Suspected or established central nervous system injury (eg, prenatal alcohol or cocaine exposure)",
"     </li>",
"     <li>",
"      ADHD symptoms interfere with other needed therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When medication is necessary for preschool children, we suggest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    rather than amphetamines or nonstimulant medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898714#H2007898714\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Preschool children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483779\">",
"    <span class=\"h2\">",
"     School-age children",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most school-aged children and adolescents (&ge;6 years of age) who meet the diagnostic criteria for ADHD and specific criteria for medication, we suggest initial treatment with stimulant medication combined with behavioral therapy, to improve core symptoms and target outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,3,11,12,14\">",
"     2,3,11,12,14",
"    </a>",
"    ]. However, nonstimulant medications may be more appropriate for certain children. Comorbid conditions must be considered in selecting a specific treatment approach.",
"   </p>",
"   <p>",
"    The values and preferences of the patient and family are critical factors in deciding whether or not to initiate medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ]. The decision of families who choose to decline medication must be respected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898686#H2007898686\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Choice of agent'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H966764713\">",
"     'Behavioral interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007892533\">",
"    <span class=\"h2\">",
"     Children who do not meet ADHD criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend behavioral interventions for children with problematic behavior who do not met the diagnostic criteria for ADHD. (See",
"    <a class=\"local\" href=\"#H966764713\">",
"     'Behavioral interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130704242\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD is a chronic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ]. Children undergoing treatment for ADHD should be monitored regularly for adherence to the treatment plan, adverse effects of therapy (for those on medications), and response to therapy (eg, the achievement of target goals and the occurrence of core symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,3,5,15\">",
"     2,3,5,15",
"    </a>",
"    ]. If the selected management strategy does not result in attainment of the target outcome, the original diagnosis, comorbid conditions, and adherence to management plan should be reevaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H14#H14\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects of medications and monitoring for adverse effects of medications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2166605#H2166605\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Managing stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of follow-up visits depends upon whether or not the child is receiving medication and how well the core symptoms and target behaviors are being controlled. Children who are not receiving medication should be seen at least twice per year, particularly during critical transitions (eg, into middle school or high school). The monitoring schedule for children receiving medication depends upon the stage of pharmacotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. It may range from weekly during the titration stage to every three or six months during the maintenance phase, depending upon adherence, coexisting conditions, and the persistence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898721#H2007898721\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130706622\">",
"    <span class=\"h3\">",
"     Response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to treatment is demonstrated by objective measurement of reduction in core symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improvement in target goals (eg, 40 to 50 percent reduction in core symptoms compared with baseline; decreased proportion of missing assignments from 60 to 20 percent per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. Core symptoms can be monitored through the use of ADHD-specific rating scales (",
"    <a class=\"graphic graphic_table graphicRef81675 \" href=\"mobipreview.htm?21/27/21949\">",
"     table 3",
"    </a>",
"    ); target symptoms can be monitored through a daily report card or periodic narrative reports from the child's teacher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. Parent reports correlate poorly with teacher reports and cannot be used as a proxy for teacher reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A toolkit that provides information about daily report cards is available through the",
"    <a class=\"external\" href=\"file://www.nichq.org/adhd_tools.html\">",
"     National Initiative for Children's Healthcare Quality",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Inadequate or lack of response to treatment may be due to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coexisting conditions (eg, language or learning disabilities, mental health disorder, psychosocial stressor) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H22#H22\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Coexisting disorders'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonadherence to the treatment plan",
"     </li>",
"     <li>",
"      Incorrect or incomplete diagnosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H13#H13\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with inadequate or lack of response to treatment, repetition of the diagnostic evaluation may be warranted, with increased focus on coexisting conditions that are associated with ADHD or mimic its symptoms (eg, sleep disorders, epilepsy, learning disorders, etc). The nonspecific improvement in behavior that occurs with stimulant medication can mask other problems",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delay the use of more appropriate interventions (eg, serotonin reuptake inhibitor for depression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H14#H14\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H484900\">",
"    <span class=\"h1\">",
"     TREATMENT MODALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H966764713\">",
"    <span class=\"h2\">",
"     Behavioral interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions include modifications in the physical and social environment that are designed to change behavior using rewards and nonpunitive consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. Behavioral techniques that are used for children with ADHD include positive reinforcement, time-out, response cost (withdrawing rewards or privileges when unwanted or problem behavior occurs), and token economy (a combination of positive reinforcement and response cost) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral interventions are preferred to medication as the initial intervention for preschool children with ADHD (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ) and are adjuncts to medication for school-aged children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,4,22-25\">",
"     2,4,22-25",
"    </a>",
"    ]. Behavioral interventions also can be used for children who have problems with inattention, hyperactivity, or impulsivity but do not meet criteria for ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898672#H2007898672\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Prerequisites'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H483779\">",
"     'School-age children'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Parent behavioral therapy is aimed at improving parent-child relationships through enhanced parenting skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/13\">",
"     13",
"    </a>",
"    ]. Behavioral interventions are most effective if parents understand the principles of behavior therapy (ie, identification of antecedents and altering the consequences of behavior) and the techniques are consistently implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/13,21\">",
"     13,21",
"    </a>",
"    ]. Parent training programs (usually weekly for 7 to 12 weeks) are available in many communities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. Clinicians can request references for a suitable behavioral therapist from professional organizations (eg,",
"    <a class=\"external\" href=\"file://www.abct.org/home/\">",
"     Association for Behavior and Cognitive Therapies",
"    </a>",
"    ) or ADHD advocacy organizations (eg,",
"    <a class=\"external\" href=\"file://www.chadd.org/\">",
"     Children and Adults with Attention Deficit Hyperactivity Disorder",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavior therapy and environmental changes that can be used by parents or teachers to shape the behavior of children with ADHD include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,7,26\">",
"     2,7,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintaining a daily schedule",
"     </li>",
"     <li>",
"      Keeping distractions to a minimum",
"     </li>",
"     <li>",
"      Providing specific and logical places for the child to keep his schoolwork, toys, and clothes",
"     </li>",
"     <li>",
"      Setting small, reachable goals (see",
"      <a class=\"local\" href=\"#H483677\">",
"       'Target goals'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Rewarding positive behavior (eg, with a &ldquo;token economy&rdquo;)",
"     </li>",
"     <li>",
"      Using charts and checklists to help the child stay \"on task\"",
"     </li>",
"     <li>",
"      Limiting choices",
"     </li>",
"     <li>",
"      Finding activities in which the child can be successful (eg, hobbies, sports)",
"     </li>",
"     <li>",
"      Using calm discipline (eg, time out, distraction, removing the child from the situation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional tips for parents of children age 6 to 12 years are available through the",
"    <a class=\"external\" href=\"file://www.nichq.org/adhd_tools.html\">",
"     National Initiative for Children's Healthcare Quality toolkit",
"    </a>",
"    , free with registration. (See",
"    <a class=\"local\" href=\"#H130702487\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are few randomized controlled trials of behavior therapy for ADHD in young children. However, in pooled analysis of eight studies in preschool children with disruptive behavior disorders (including children at risk for ADHD), parent behavior training was associated with improved parent-reported child behavior (standardized mean difference -0.68, 95% CI -0.88 to -0.47) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/20\">",
"     20",
"    </a>",
"    ]. The standardized mean difference (also called the effect size) describes the extent to which the performance in the treatment group differed from that in the control group; by consensus, differences of 0.2, 0.5, and 0.8 are considered small, moderate, and large, respectively. The addition of school or daycare interventions to parent behavior training appeared to have some benefit for children from families of lower socioeconomic status. The long-term effects of behavior therapy for ADHD in have not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standardized training programs for parents of preschool children with disruptive behavior disorders (including symptoms of ADHD) that have been evaluated in systematic reviews include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incredible Years Parenting Program",
"      <span class=\"nowrap\">",
"       (file://www.incredibleyears.com/index.asp)",
"      </span>",
"     </li>",
"     <li>",
"      New Forest Parenting Program (specifically designed to address ADHD symptoms)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.pcit.org/\">",
"       Parent-Child Interaction Therapy",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.triplep.net/\">",
"       Positive Parenting Program",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most systematic reviews, behavioral interventions alone do not appear to reduce the core symptoms of ADHD in school-aged children, but may improve other problem behaviors (eg, aggression, parent-child relations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. However, one meta-analysis found behavioral interventions to be effective with the effect size varying according to study design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/30\">",
"     30",
"    </a>",
"    ]. The conclusions of the systematic reviews are limited by the quality of the included studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/28,29,31,32\">",
"     28,29,31,32",
"    </a>",
"    ]. Problems include insufficient description of the intervention and the complexity of the child's family, school, social, and peer environments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications, with or without",
"    <span class=\"nowrap\">",
"     behavioral/psychologic",
"    </span>",
"    interventions are the first-line therapy for school-aged children (&ge;6 years) and adolescents who meet diagnostic criteria for ADHD (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ]. Medications may be used as an adjunct to behavioral interventions for preschool children (4 through 5 years) who fail to respond to behavioral interventions alone. However, the values and preferences of the patient and family are critical factors in deciding whether or not to initiate medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"     2",
"    </a>",
"    ]. The decision of families who choose to decline medication must be respected. (See",
"    <a class=\"local\" href=\"#H268239\">",
"     'Overview of management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of ADHD with medications, including the choice of agent and dose titration, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy uses both",
"    <span class=\"nowrap\">",
"     behavioral/psychologic",
"    </span>",
"    interventions and medications. Combination therapy may be warranted in preschool children who do not respond to behavioral interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/3\">",
"     3",
"    </a>",
"    ]. In a systematic review and a meta-analysis, combination therapy with medications and",
"    <span class=\"nowrap\">",
"     behavior/psychologic",
"    </span>",
"    therapy was superior to",
"    <span class=\"nowrap\">",
"     behavior/psychological",
"    </span>",
"    therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/28,33\">",
"     28,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H483772\">",
"     'Preschool children'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Combination therapy may be beneficial for school-aged children and adolescents who have a suboptimal response to pharmacotherapy, have a coexisting condition, or experience stressors in family life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/3\">",
"     3",
"    </a>",
"    ]. In systematic reviews of randomized trials (including the Multimodal Treatment Study of Children with ADHD), combined medication and behavior treatment was no more effective than medication treatment alone in improving core symptoms of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/28,33,34\">",
"     28,33,34",
"    </a>",
"    ]. However, children receiving combined treatment may require lower doses of medication and achieve greater improvement in non-ADHD symptoms (eg,",
"    <span class=\"nowrap\">",
"     oppositional/aggressive,",
"    </span>",
"    internalizing, teacher-rated social skills, parent-child relations, and reading achievement) than children receiving medication alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/24,34\">",
"     24,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H483779\">",
"     'School-age children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     School-based interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;School-based interventions may include the provision of tutoring or resource room support (either in an exclusive setting or within the classroom), classroom modifications, accommodations, or behavioral interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7,26,35\">",
"     7,26,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Classroom modifications and accommodations may include having assignments written on the board, sitting near the teacher, having extended time to complete tasks, being allowed to take tests in a less distracting environment, or receiving a private signal from the teacher when is the child \"off-task\". The teacher's completion of a daily report card facilitates the monitoring of symptoms and the need for changes in the treatment plan. (See",
"    <a class=\"local\" href=\"#H130706622\">",
"     'Response to treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The school also may provide behavior management programs that target ADHD symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enhanced academic and social function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. Information for teachers of children with ADHD is available through the",
"    <a class=\"external\" href=\"file://www.help4adhd.org/en/education\">",
"     National Resource Center on ADHD",
"    </a>",
"   </p>",
"   <p>",
"    A systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/20\">",
"     20",
"    </a>",
"    ] found two cohort studies (and one extension) that demonstrated that classroom-based programs to enhance academic skills were effective in improving achievement scores in multiple domains, but the benefits are sustained only as long as the intervention is continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADHD is considered to be a disability under the Individuals with Disabilities Education Act (IDEA [PL-101-476]). Under IDEA, children with ADHD may qualify for special education or related services. Alternatively, they may qualify for appropriate accommodations within the regular classroom setting under Section 504 of the Rehabilitation Act of 1973 (",
"    <a class=\"graphic graphic_table graphicRef68063 \" href=\"mobipreview.htm?11/20/11597\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, the Americans with Disabilities Act may provide individuals with ADHD reasonable accommodations in secular private schools and post-secondary education (",
"    <a class=\"graphic graphic_table graphicRef80545 \" href=\"mobipreview.htm?3/19/3389\">",
"     table 5",
"    </a>",
"    ). The completion of a daily report card or a &ldquo;communication book&rdquo; to facilitate communication between the parents and the teachers may be suggested as an accommodation under a 504 plan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=see_link&amp;anchor=H9#H9\">",
"     \"Support services for the care of chronically ill children\", section on 'Education'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link&amp;anchor=H4#H4\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\", section on 'Laws affecting the education of students with disabilities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28013725\">",
"    <span class=\"h2\">",
"     Social skills training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficits in social skills and problems with peers require direct targeting over the long-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/39\">",
"     39",
"    </a>",
"    ]. Social skills deficits can be addressed through social skills groups or similar interventions (in or out of the school setting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1404650936\">",
"    <span class=\"h2\">",
"     Psychotherapy interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy interventions are distinct from behavioral interventions. Psychological interventions are directed toward the child (rather than the environment) and designed to change the child&rsquo;s emotional status (eg, play therapy) or thought patterns (eg, cognitive-behavior therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally do not suggest psychological interventions for children with ADHD unless they have coexisting conditions that require psychological interventions. Psychologic interventions have not been proven beneficial for the core symptoms ADHD in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"     7",
"    </a>",
"    ]. Gains achieved with psychologic interventions in the treatment setting usually do not transfer to other settings (eg, classroom or home).",
"   </p>",
"   <p>",
"    However, cognitive behavioral therapy may be a helpful adjunct to medications for adolescents with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Psychologic interventions for adolescents may address skill deficits (eg, organization, planning)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coexisting psychiatric problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/43\">",
"     43",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192030975\">",
"    <span class=\"h2\">",
"     Dietary interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450433671\">",
"    <span class=\"h3\">",
"     Elimination diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally do not suggest elimination diets for children with ADHD, but decisions regarding trials of dietary interventions for ADHD must be made on a case-by-case basis. Some experts suggest that a short (no more than five-week) trial of an elimination diet may be warranted for certain children (eg, those whose caregivers are concerned about the use of and potential side effects of pharmacologic agents and are motivated to comply with the diet) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. If the decision is made to try an elimination diet, the diet should be supervised by the child&rsquo;s healthcare provider and a dietician to ensure adequate nutritional intake. If behavior improves during the elimination diet, restricted foods can be added back weekly, one component at a time, to identify problematic foods that should be excluded from a less restrictive permanent diet.",
"   </p>",
"   <p>",
"    The influence of diet on attention, hyperactivity, and behavior is controversial. Dietary factors (eg, food additives, food allergy or intolerance, etc) generally do not impact behavior to a clinically significant level and do not account for the majority of cases of ADHD. However, a small subset of children may demonstrate mild adverse behavioral effects in response to particular dietary components and improvements in behavior when these components are eliminated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4954?source=see_link&amp;anchor=H12#H12\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\", section on 'Dietary influences'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systematic reviews and meta-analyses of randomized trials with methodologic limitations suggest that some children with ADHD respond favorably to elimination diets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. In a 2012 meta-analysis of five randomized crossover studies, restriction diets reduced ADHD symptoms in children (effect size 0.29, 95% CI 0.16-0.52) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/49\">",
"     49",
"    </a>",
"    ]. Masked challenge with specific food colors had a small effect on parent-reported ADHD symptoms (20 studies, 794 participants, effect size 0.18, 95% CI 0.08-0.29), and a non-significant effect on teacher-reported symptoms (10 studies, 323 participants effect size 0.07, 95% CI -0.03-0.18). This discrepancy between parent and health",
"    <span class=\"nowrap\">",
"     professional/teacher",
"    </span>",
"    report of symptoms has been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/48,53\">",
"     48,53",
"    </a>",
"    ]. The long-term effects of dietary elimination on nutritional status are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither the American Academy of Pediatrics nor the United Kingdom&rsquo;s National Institute for Health and Clinical Excellence (NICE) guidelines routinely recommend elimination diets for the treatment of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, the NICE guidelines indicate that referral to a dietician may be warranted if perceived links between specific foods or beverages and behavior are corroborated with a food diary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450433678\">",
"    <span class=\"h3\">",
"     Essential fatty acid supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest essential fatty acid supplementation for children with ADHD. Some studies have noted decreased fatty acid concentrations in the serum of children with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. However, evidence that fatty acid supplementation improves core symptoms in children with ADHD is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/52,58,59\">",
"     52,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of randomized and quasi-randomized trials comparing omega-3",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    omega-6 fatty acid with placebo supplementation in children with ADHD (diagnosed with validated criteria), there were no differences in parent- or teacher-rated ADHD symptoms (overall), inattention, or",
"    <span class=\"nowrap\">",
"     hyperactivity/impulsivity",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/58\">",
"     58",
"    </a>",
"    ]. Pooled analysis of two small trials (97 participants) found some evidence of improvement in overall ADHD symptoms or parent-rated ADHD symptoms among children supplemented with both omega-3 and omega-6 fatty acids (risk ratio 2.19 95% CI 1.04 to 4.62). Few of the studies included in the meta-analysis were of high quality. Methodologic limitations included small sample size, variable inclusion criteria, variable type and dose of supplement, and short duration of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2011 meta-analysis of 10 randomized trials (699 participants), omega-3-fatty acid supplementation was associated with improved ADHD symptoms in children with a diagnosis of ADHD or symptoms of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/59\">",
"     59",
"    </a>",
"    ]. The effect size was small to moderate compared with that of pharmacologic therapies (0.31 versus approximately 1.0 and 0.7, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2,59,60\">",
"     2,59,60",
"    </a>",
"    ]. Possible explanations for the variable findings in the two meta-analyses include differences in population (children diagnosed with ADHD versus children with ADHD diagnosis or symptoms) and outcome measures (separate versus pooled parent- and teacher-reported symptoms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542114657\">",
"    <span class=\"h2\">",
"     Other alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medicine (CAM) therapies may be considered or employed by as many as 64 percent of patients with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/61\">",
"     61",
"    </a>",
"    ]. CAM therapies often are used by patients without the explicit knowledge of the primary care provider [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. It is important for primary care providers to ask their patients whether they have tried any CAM therapies for ADHD so that the risks and benefits of such therapies can be discussed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to elimination diets and fatty acid supplementation, other complementary and alternative (CAM) therapies that have been suggested in the management of ADHD include vision training, megavitamins, herbal and mineral supplements (eg, St. John's wort),",
"    <span class=\"nowrap\">",
"     neurofeedback/biofeedback,",
"    </span>",
"    chelation, and applied kinesiology, among others. Most of these interventions have not been proven efficacious in blinded randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/66-71\">",
"     66-71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical use of St. John's wort\", section on 'Attention deficit/hyperactivity disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several alternative therapies, including chelation and megavitamins, may have serious adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7,72-74\">",
"     7,72-74",
"    </a>",
"    ]. Additional harms include the potential failure and setback for the child when symptoms and problems persist, as well as unnecessary expenses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians can help families who choose to explore CAM therapies to make thoughtful choices by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7,75\">",
"     7,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reviewing the stated goals or effects for a given treatment",
"     </li>",
"     <li>",
"      Reviewing the evidence of benefits and potential adverse effects",
"     </li>",
"     <li>",
"      Encourage families who want to try CAM therapies to try them one at a time and to monitor target goals and core symptoms to determine effect",
"     </li>",
"     <li>",
"      Encouraging families to determine a time frame in which they expect behavior changes to occur",
"     </li>",
"     <li>",
"      Encouraging families to use evidence-based behavioral interventions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      medications at the same time that they are exploring CAM therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician also can try to redirect patients and families who are using potentially harmful CAM therapies (eg, megavitamins) to safer (if still unproven) lifestyle therapies (eg, yoga, massage therapy). Suggestions for lifestyle therapies for ADHD are available through the",
"    <a class=\"external\" href=\"file://www.wakehealth.edu/center-for-integrative-medicine/specialty-services/pediatric-second-opinion-clinic.htm\">",
"     Wake Forest Baptist Health Center for Integrative Medicine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35529?source=see_link&amp;anchor=H27285936#H27285936\">",
"     \"Overview of complementary and alternative medicine in pediatrics\", section on 'Discussing CAM therapies with patients and families'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the information about prognosis in children with ADHD is derived from small cohort studies of male patients who were evaluated and treated for ADHD in psychiatric clinics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/64,76-83\">",
"     64,76-83",
"    </a>",
"    ]. The generalizability of the information to other patient groups is limited. Long-term follow-up (six to eight years) of the MTA study cohort suggests that functioning during adolescence is predicted by the initial clinical presentation (including severity of symptoms, and comorbid conduct problems), intellect, social advantage, and the strength of ADHD response to any mode of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Injury and self-injury",
"    </strong>",
"    &ndash; Children with ADHD or symptoms of ADHD are at greater risk for incurring intentional and unintentional injury than are children without these symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/85-91\">",
"     85-91",
"    </a>",
"    ]. In a review of medical, pharmaceutical, and disability claims for injuries or poisoning treatments, individuals with ADHD were more likely to have at least one claim related to unintentional injury than controls (28 versus 19 percent for children, 32 versus 23 percent for adolescents, and 38 versus 18 percent for adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 140 girls with ADHD diagnosed at age 6 to 12 years (93 with combined type [ADHD-C], 47 with inattentive type [ADHD-I]), those with ADHD-C were more likely to have attempted suicide during the 10-year follow-up than those with ADHD-I or controls (22, 8, and 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/90\">",
"     90",
"    </a>",
"    ]. Self-injury was also more common among girls with ADHD-C than girls with ADHD-I or controls (51, 29, and 19 percent, respectively).",
"   </p>",
"   <p>",
"    <strong>",
"     Driving",
"    </strong>",
"    &ndash; Adolescents with ADHD are two to four times more likely than those without the disorder to have motor vehicle accidents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/92\">",
"     92",
"    </a>",
"    ]. They also are more likely to have their driving licenses suspended or revoked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/93\">",
"     93",
"    </a>",
"    ]. In randomized trials, driving performance improves with stimulant medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Education",
"    </strong>",
"    &ndash; Follow-up studies of children with ADHD into adolescence consistently indicate impaired academic functioning (eg, completion of less schooling, lower achievement scores, failure of more courses) compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/43,63,64,76,90,97-99\">",
"     43,63,64,76,90,97-99",
"    </a>",
"    ]. This is particularly true for children with the inattentive or combined subtype of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/100\">",
"     100",
"    </a>",
"    ]. In the few studies in which subjects were followed into adulthood, the findings persisted (25 to 33 percent of probands versus 1 to 9 percent of controls dropped out of high school; 15 to 19 percent of probands versus 50 to 64 percent of controls had completed a bachelor's or higher level degree) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/76,79,80,83,101\">",
"     76,79,80,83,101",
"    </a>",
"    ]. Impaired academic function appears to persist, even in those children who no longer meet criteria for diagnosis of ADHD in adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Substance use",
"    </strong>",
"    &ndash; Whether children with ADHD have an increased risk of engaging in substance use during adolescence or adulthood is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/76\">",
"     76",
"    </a>",
"    ]. Several follow-up studies reported an increased prevalence of nonalcohol substance use disorder among probands (12 to 16 percent versus 4 percent in controls) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/77,79,83\">",
"     77,79,83",
"    </a>",
"    ], whereas others did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/80,90,102-105\">",
"     80,90,102-105",
"    </a>",
"    ]. The increased prevalence of substance use is present predominantly among patients who have comorbid conduct or antisocial disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/106-111\">",
"     106-111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of engaging in substance use in adolescence may be related to the pharmacologic treatment of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In a meta-analysis of six longitudinal studies evaluating substance use disorders during adolescence or adulthood among children and adolescents with ADHD, the pooled estimate of the odds ratio indicated a 1.9-fold reduction in substance use disorders among those who received pharmacotherapy (ie, stimulants) compared with those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/114\">",
"     114",
"    </a>",
"    ]. Studies in which the subjects were followed to adolescence showed a greater protective effect of pharmacotherapy than those in which the subjects were followed to adulthood (odds ratio 5.8 versus 1.4). However, no effect of medication for ADHD (whether analyzed by original treatment group, medication at follow-up, or cumulative stimulant therapy) was found in eight-year follow-up of participants in the Multimodal Treatment Study of Children with ADHD (not included in the meta-analysis), in which children (7 to 9.9 years old at the time of enrollment) were randomly assigned to 14 months of medication, behavior therapy, combined medication and behavioral therapy, or standard community care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Persistence of symptoms",
"    </strong>",
"    &ndash; Prevalence and natural history data suggest that one- to two-thirds of the 3 to 10 percent of children diagnosed with ADHD continue to manifest appreciable ADHD symptoms into adult life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/91,106,116\">",
"     91,106,116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32761?source=see_link&amp;anchor=H2#H2\">",
"     \"Adult attention deficit hyperactivity disorder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study of 140 girls with ADHD diagnosed at age 6 to 12 years (93 with ADHD-C, 47 ADHD-I), 115 were available for the 10-year follow-up (41 with ADHD-I and 87 with ADHD-C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/90\">",
"     90",
"    </a>",
"    ]. Among girls diagnosed with ADHD-I during childhood, 39 percent continued to meet criteria for ADHD-I, 22 percent met criteria for ADHD-C, and 39 percent no longer met criteria for ADHD. Among girls diagnosed with ADHD-C during childhood, 37 percent continued to meet criteria for ADHD-C, 2 percent met criteria for",
"    <span class=\"nowrap\">",
"     hyperactive/impulsive",
"    </span>",
"    ADHD, 17 percent met criteria for ADHD-I, and 44 percent no longer met criteria for ADHD.",
"   </p>",
"   <p>",
"    <strong>",
"     Employment",
"    </strong>",
"    &ndash; In studies that followed children with ADHD into early adulthood, the rate of employment of ADHD probands did not differ from that of controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. However, in a prospective male cohort that was followed for 33 years (mean age 41 years), fewer probands than controls were employed (83 versus 95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/83\">",
"     83",
"    </a>",
"    ]. Probands were reported to have lower status jobs and to perform poorly compared with controls when rated by their employers in various areas of work performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/76,83\">",
"     76,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Antisocial personality",
"    </strong>",
"    &ndash; Children who have ADHD are at increased risk to develop antisocial personality disorder (ASPD) and behaviors in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/76,83,107\">",
"     76,83,107",
"    </a>",
"    ]. In studies that followed children with ADHD into adulthood, the prevalence of ASPD ranges from 12 to 23 percent in probands (predominantly with the hyperactive-impulsive subtype of ADHD) versus 2 to 3 percent in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/77,79,80,83\">",
"     77,79,80,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of developing ASPD appears to be independent of comorbid conduct disorder in childhood because children with comorbid problems were excluded from several study cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In an observational study, 54 percent of 147 ADHD patients self-reported having been arrested at least once by age 21 years (compared with 37 percent of 73 community controls); 24 percent of ADHD patients had been arrested for misdemeanors (compared with 11 percent of controls) and 27 percent for felony (compared with 11 percent of controls) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/61/32730/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130702487\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Initiative for Children's Healthcare Quality (NICHQ), in conjunction with North Carolina&rsquo;s Center for Child Health Improvement, and the American Academy of Pediatrics (AAP), has developed a toolkit to assist primary care practitioners in the evaluation and management of school-age children with ADHD. The toolkit includes information for parents, copies of ADHD-specific questionnaires for parents and teachers, and an initial primary care evaluation form. It can be downloaded without charge through the",
"    <a class=\"external\" href=\"file://www.nichq.org/adhd_tools.html\">",
"     National Initiative for Children's Healthcare Quality",
"    </a>",
"    but may require registration. A revised edition of the toolkit, which also includes tools and resources for preschool children and adolescents, is available for purchase through the American Academy of Pediatrics.",
"   </p>",
"   <p>",
"    Resources for families of children with ADHD are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef60584 \" href=\"mobipreview.htm?26/42/27308\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Information for teachers of children with ADHD is available through the",
"    <a class=\"external\" href=\"file://www.help4adhd.org/en/education\">",
"     National Resource Center on ADHD",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/32/11778?source=see_link\">",
"       \"Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=see_link\">",
"       \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/53/35668?source=see_link\">",
"       \"Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention deficit hyperactivity disorder (ADHD) is a chronic condition; education of patients, families, and teachers regarding the diagnosis is an integral part of treatment. Management centers on the achievement of target outcomes, which are chosen in collaboration with the child, parents, and school personnel. Coexisting conditions must be treated concurrently with ADHD. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of ADHD may involve",
"      <span class=\"nowrap\">",
"       behavioral/psychologic",
"      </span>",
"      interventions, medication,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      educational interventions, alone or in combination. Decisions regarding the choice of therapy should involve the patient and his or her parents. (See",
"      <a class=\"local\" href=\"#H130698002\">",
"       'Involvement of patient and family'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ADHD in children 4 to 18 years of age without comorbid conditions can usually be managed by the primary care provider. Indications for referral to or consultation with a specialist (eg, developmental behavioral pediatrician, child neurologist, psychopharmacologist, child psychiatrist, clinical child psychologist) may include (see",
"      <a class=\"local\" href=\"#H2162173\">",
"       'Indications for referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Coexisting psychiatric conditions (eg, oppositional defiant disorder, conduct disorder, substance abuse, emotional problems)",
"     </li>",
"     <li>",
"      Coexisting neurologic, or medical conditions (eg, seizures, tics, autism spectrum disorder, sleep disorder)",
"     </li>",
"     <li>",
"      Lack of response to a controlled trial of stimulant therapy or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For preschool children (age 4 through 5 years) who meet the diagnostic criteria for ADHD (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ), we recommend behavior therapy rather than medication as the initial therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The addition of medication to behavior therapy may be indicated if target behaviors do not improve with behavioral therapy and the child&rsquo;s function continues to be impaired. When medication is necessary for preschool children, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      rather than amphetamines or nonstimulants (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H483772\">",
"       'Preschool children'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898714#H2007898714\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Preschool children'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most school-aged children (&ge;6 years) and adolescents with ADHD who meet specific criteria (",
"      <a class=\"graphic graphic_table graphicRef66213 \" href=\"mobipreview.htm?6/44/6860\">",
"       table 6",
"      </a>",
"      ), we suggest treatment with medication rather than behavior therapy alone or no intervention (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). However, decisions regarding the choice of therapy should involve the patient and his or her parents. When the decision is made to try medications, we suggest a stimulant as the first line agent (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H483779\">",
"       'School-age children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898686#H2007898686\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Choice of agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For school-aged children (&ge;6 years) and adolescents with ADHD, we suggest that behavioral interventions be added to medication therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Adding",
"      <span class=\"nowrap\">",
"       behavioral/psychologic",
"      </span>",
"      therapy to stimulant therapy in school-aged children and adolescents does not provide additional benefit for core symptoms of ADHD, but may affect symptoms of coexisting conditions (eg,",
"      <span class=\"nowrap\">",
"       oppositional/aggressive",
"      </span>",
"      behavior) and lower the dose of stimulant therapy necessary to achieve the desired effects. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children being treated for ADHD should be monitored regularly for adherence to the treatment plan, achievement of target goals, occurrence of core symptoms, and adverse effects of therapy. The frequency of follow-up depends upon the management strategy. (See",
"      <a class=\"local\" href=\"#H130704242\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with ADHD may require changes in their educational programming, including tutoring, resource room support, or special classes (eg, inclusion classes, blended classes). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'School-based interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest elimination diets for most children with ADHD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, a short trial (no more than five weeks) of an elimination diet may be an option for children with ADHD whose caregivers are concerned about the use and potential side effects of pharmacologic agents and are motivated to comply with the diet. (See",
"      <a class=\"local\" href=\"#H450433671\">",
"       'Elimination diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest essential fatty acid supplementation for children with ADHD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H450433678\">",
"       'Essential fatty acid supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with ADHD have an increased risk of intentional and unintentional injuries; those who drive have an increased risk of motor vehicle accidents. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, American Psychiatric Association, Washington, DC 2000. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/2\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/3\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. www.nice.org.uk/CG72 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/5\">",
"      Hill P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/6\">",
"      Jessop DJ, Stein RE. Providing comprehensive health care to children with chronic illness. Pediatrics 1994; 93:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/7\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics, National Initiative for Children's Healthcare Quality. How to establish a school-home daily report card. file://www.nichq.org/toolkits_publications/complete_adhd/12HowToEstabSchlHomeDailyRepCa.pdf (Accessed on November 17, 2011).",
"    </li>",
"    <li>",
"     Green M, Wong M, Atkins D, et al. Diagnosis of Attention Deficit/Hyperactivity Disorder. Technical Review 3. AHCPR publication 99-0050, US Dept of Health and Human Services; Agency for Health Care Policy and Research, Rockville, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/10\">",
"      Horst RO, Hendren RL. Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD). Essent Psychopharmacol 2005; 6:250.",
"     </a>",
"    </li>",
"    <li>",
"     Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people. file://www.sign.ac.uk/guidelines/fulltext/112/index.html (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/12\">",
"      Taylor E, D&ouml;pfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1:I7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/13\">",
"      Kaplan A, Adesman A. Clinical diagnosis and management of attention deficit hyperactivity disorder in preschool children. Curr Opin Pediatr 2011; 23:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/14\">",
"      Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/15\">",
"      Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/16\">",
"      Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998; 59 Suppl 7:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/17\">",
"      Lavigne JV, Dulcan MK, LeBailly SA, Binns HJ. Can parent reports serve as a proxy for teacher ratings in medication management of attention-deficit hyperactivity disorder? J Dev Behav Pediatr 2012; 33:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/18\">",
"      Wolraich ML, Lambert EW, Bickman L, et al. Assessing the impact of parent and teacher agreement on diagnosing attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/19\">",
"      Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:40.",
"     </a>",
"    </li>",
"    <li>",
"     Charach A, Dashti B, Carson P, et al. Attention deficit hyperactivity disorder: Effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. AHRQ Publication No. 12-EHC003, Agency for Healthcare Research and Quality, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/21\">",
"      Floet AM, Scheiner C, Grossman L. Attention-deficit/hyperactivity disorder. Pediatr Rev 2010; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/22\">",
"      Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry 1999; 38:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/23\">",
"      Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998; 27:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/24\">",
"      Carlson CL, Pelham WE Jr, Milich R, Dixon J. Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 1992; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/25\">",
"      Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997; 36:85S.",
"     </a>",
"    </li>",
"    <li>",
"     Understanding ADHD. Information for parents about attention-deficit/hyperactivity disorder. American Academy of Pediatrics, Elk Grove Village, IL 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/27\">",
"      Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/28\">",
"      Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115:e749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/29\">",
"      Zwi M, Jones H, Thorgaard C, et al. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011; :CD003018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/30\">",
"      Fabiano GA, Pelham WE Jr, Coles EK, et al. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clin Psychol Rev 2009; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/31\">",
"      Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999; :i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/32\">",
"      Storeb&oslash; OJ, Skoog M, Damm D, et al. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011; :CD008223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/33\">",
"      Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 2008; 28:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/34\">",
"      A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     Miller KJ, Wender EH. Attention deficit/hyperactivity disorder. In: Primary Pediatric Care, 4th ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.756.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/36\">",
"      Volpe RJ, DuPaul GJ, Jitendra AK, et al. Consultation-based academic interventions for children with attention deficit hyperactivity disorder: effects on reading and mathematics outcomes at 1-year follow-up. School Psych Rev 2009; 38:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/37\">",
"      Evans SE, Serpell ZN, Schultz BK, et al. Cumulative benefits of secondary school-based treatment of students with attention deficit hyperactivity disorder. School Psych Rev 2007; 36:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/38\">",
"      Jitendra AK, DuPaul GJ, Volpe RJ, et al. Consultation-based academic intervention for children with attention deficit hyperactivity disorder: school functioning outcomes. School Psych Rev 2007; 26:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/39\">",
"      Hoza B. Peer functioning in children with ADHD. Ambul Pediatr 2007; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/40\">",
"      Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 2005; 6:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/41\">",
"      Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005; 43:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/42\">",
"      Barkley RA. Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiatr Pract 2004; 10:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/43\">",
"      Stein DS, Blum NJ, Barbaresi WJ. Developmental and behavioral disorders through the life span. Pediatrics 2011; 128:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/44\">",
"      Ghuman JK. Restricted elimination diet for ADHD: the INCA study. Lancet 2011; 377:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/45\">",
"      Kemp A. Food additives and hyperactivity. BMJ 2008; 336:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/46\">",
"      Eigenmann PA, Haenggeli CA. Food colourings, preservatives, and hyperactivity. Lancet 2007; 370:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/47\">",
"      Rojas NL, Chan E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev 2005; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/48\">",
"      Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. J Dev Behav Pediatr 2004; 25:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/49\">",
"      Nigg JT, Lewis K, Edinger T, Falk M. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry 2012; 51:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/50\">",
"      Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012; 129:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/51\">",
"      Stevens LJ, Kuczek T, Burgess JR, et al. Dietary sensitivities and ADHD symptoms: thirty-five years of research. Clin Pediatr (Phila) 2011; 50:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/52\">",
"      Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological Interventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological Treatments. Am J Psychiatry 2013; 170:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/53\">",
"      Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled, artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004; 89:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/54\">",
"      Bekaro��lu M, Aslan Y, Gedik Y, et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996; 37:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/55\">",
"      Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 2007; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/56\">",
"      Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995; 62:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/57\">",
"      Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009; 51:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/58\">",
"      Gillies D, Sinn JKh, Lad SS, et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012; 7:CD007986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/59\">",
"      Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011; 50:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/60\">",
"      Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006; 8:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/61\">",
"      Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002; 23:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/62\">",
"      Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005; 41:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/63\">",
"      Fischer M, Barkley RA, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 1990; 58:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/64\">",
"      Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. II. Status of subjects without a mental disorder. Arch Gen Psychiatry 1988; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/65\">",
"      Gilmour J, Harrison C, Asadi L, et al. Natural health product-drug interactions: evolving responsibilities to take complementary and alternative medicine into account. Pediatrics 2011; 128 Suppl 4:S155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/66\">",
"      Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/67\">",
"      Lilienfeld SO. Scientifically unsupported and supported interventions for childhood psychopathology: a summary. Pediatrics 2005; 115:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/68\">",
"      Skokauskas N, McNicholas F, Masaud T, Frodl T. Complementary medicine for children and young people who have attention deficit hyperactivity disorder. Curr Opin Psychiatry 2011; 24:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/69\">",
"      Lofthouse N, Arnold LE, Hersch S, et al. A review of neurofeedback treatment for pediatric ADHD. J Atten Disord 2012; 16:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/70\">",
"      Weber W, Vander Stoep A, McCarty RL, et al. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA 2008; 299:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/71\">",
"      Lofthouse N, Arnold LE, Hurt E. Current status of neurofeedback for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2012; 14:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/72\">",
"      Voelker R. FDA warning targets OTC chelation products. JAMA 2010; 304:2112.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Chelation products: Unapproved over-the-counter drugs -- consumer warning. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm229454.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/74\">",
"      Haslam RH, Dalby JT, Rademaker AW. Effects of megavitamin therapy on children with attention deficit disorders. Pediatrics 1984; 74:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/75\">",
"      Kemper KJ, Vohra S, Walls R, et al. American Academy of Pediatrics. The use of complementary and alternative medicine in pediatrics. Pediatrics 2008; 122:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/76\">",
"      Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/77\">",
"      Mannuzza S, Klein RG, Bessler A, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/78\">",
"      Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry 1985; 42:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/79\">",
"      Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/80\">",
"      Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/81\">",
"      Weiss G, Hechtman L, Perlman T. Hyperactives as young adults: school, employer, and self-rating scales obtained during ten-year follow-up evaluation. Am J Orthopsychiatry 1978; 48:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/82\">",
"      Biederman J, Petty CR, Evans M, et al. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res 2010; 177:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/83\">",
"      Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012; 69:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/84\">",
"      Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/85\">",
"      Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004; 35:346.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/86\">",
"      DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998; 102:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/87\">",
"      Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/88\">",
"      Lam LT. Attention deficit disorder and hospitalization owing to intra- and interpersonal violence among children and young adolescents. J Adolesc Health 2005; 36:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/89\">",
"      Pastor PN, Reuben CA. Identified attention-deficit/hyperactivity disorder and medically attended, nonfatal injuries: US school-age children, 1997-2002. Ambul Pediatr 2006; 6:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/90\">",
"      Hinshaw SP, Owens EB, Zalecki C, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. J Consult Clin Psychol 2012; 80:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/91\">",
"      Barbaresi WJ, Colligan RC, Weaver AL, et al. Mortality, ADHD, and Psychosocial Adversity in Adults With Childhood ADHD: A Prospective Study. Pediatrics 2013; 131:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/92\">",
"      Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996; 98:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/93\">",
"      Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 27:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/94\">",
"      Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 2006; 118:e704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/95\">",
"      Verster JC, Bekker EM, de Roos M, et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. J Psychopharmacol 2008; 22:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/96\">",
"      Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the manchester driving behavior questionnaire. J Adolesc Health 2012; 51:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/97\">",
"      Weiss G, Hechtman L, Perlman T, et al. Hyperactives as young adults: a controlled prospective ten-year follow-up of 75 children. Arch Gen Psychiatry 1979; 36:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/98\">",
"      Lambert NM. Adolescent outcomes for hyperactive children. Perspectives on general and specific patterns of childhood risk for adolescent educational, social, and mental health problems. Am Psychol 1988; 43:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/99\">",
"      Fergusson DM, Lynskey MT, Horwood LJ. Attentional difficulties in middle childhood and psychosocial outcomes in young adulthood. J Child Psychol Psychiatry 1997; 38:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/100\">",
"      Pingault JB, Tremblay RE, Vitaro F, et al. Childhood trajectories of inattention and hyperactivity and prediction of educational attainment in early adulthood: a 16-year longitudinal population-based study. Am J Psychiatry 2011; 168:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/101\">",
"      Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/102\">",
"      Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003; 111:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/103\">",
"      Ernst M, Luckenbaugh DA, Moolchan ET, et al. Behavioral predictors of substance-use initiation in adolescents with and without attention-deficit/hyperactivity disorder. Pediatrics 2006; 117:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/104\">",
"      Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/105\">",
"      Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008; 162:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/106\">",
"      Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/107\">",
"      Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004; 45:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/108\">",
"      Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/109\">",
"      Lynskey MT, Fergusson DM. Childhood conduct problems, attention deficit behaviors, and adolescent alcohol, tobacco, and illicit drug use. J Abnorm Child Psychol 1995; 23:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/110\">",
"      Brook DW, Brook JS, Zhang C, Koppel J. Association between attention-deficit/hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediatr Adolesc Med 2010; 164:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/111\">",
"      Serra-Pinheiro MA, Coutinho ES, Souza IS, et al. Is ADHD a Risk Factor Independent of Conduct Disorder for Illicit Substance Use? A Meta-Analysis and Metaregression Investigation. J Atten Disord 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/112\">",
"      Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104:e20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/113\">",
"      Goldstein BI. Do stimulants prevent substance use and misuse among youth with attention-deficit/hyperactivity disorder? The answer is still maybe. J Am Acad Child Adolesc Psychiatry 2013; 52:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/114\">",
"      Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/115\">",
"      Molina BS, Hinshaw SP, Eugene Arnold L, et al. Adolescent Substance Use in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a Function of Childhood ADHD, Random Assignment to Childhood Treatments, and Subsequent Medication. J Am Acad Child Adolesc Psychiatry 2013; 52:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/61/32730/abstract/116\">",
"      Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001; 931:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 623 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32730=[""].join("\n");
var outline_f31_61_32730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197690673\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007891978\">",
"      Care coordination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130698002\">",
"      Involvement of patient and family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H483677\">",
"      Target goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1404650528\">",
"      Treatment of coexisting conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2162173\">",
"      Indications for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268239\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H483772\">",
"      Preschool children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H483779\">",
"      School-age children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007892533\">",
"      Children who do not meet ADHD criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130704242\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H130706622\">",
"      - Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H484900\">",
"      TREATMENT MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H966764713\">",
"      Behavioral interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      School-based interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28013725\">",
"      Social skills training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1404650936\">",
"      Psychotherapy interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192030975\">",
"      Dietary interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450433671\">",
"      - Elimination diets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450433678\">",
"      - Essential fatty acid supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542114657\">",
"      Other alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130702487\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/27/11709\" title=\"table 1\">",
"      DSM-IV-TR criteria for ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/42/27308\" title=\"table 2\">",
"      ADHD resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/27/21949\" title=\"table 3\">",
"      Behavior rating scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/20/11597\" title=\"table 4\">",
"      Rehabilitation Act Section 504",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/19/3389\" title=\"table 5\">",
"      Americans with Disabilities Act",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/44/6860\" title=\"table 6\">",
"      Initiation ADHD drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34423?source=related_link\">",
"      Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=related_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=related_link\">",
"      Definitions of specific learning disability and laws pertaining to learning disabilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/32/11778?source=related_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=related_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/53/35668?source=related_link\">",
"      Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=related_link\">",
"      Support services for the care of chronically ill children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_61_32731="Reduced sensit TH";
var content_f31_61_32731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of thyroid function test abnormalities in syndromes of reduced sensitivity to thyroid hormone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Syndrome",
"      </td>",
"      <td class=\"subtitle1\">",
"       FT",
"       <sub>",
"        4",
"       </sub>",
"      </td>",
"      <td class=\"subtitle1\">",
"       FT",
"       <sub>",
"        3",
"       </sub>",
"      </td>",
"      <td class=\"subtitle1\">",
"       rT",
"       <sub>",
"        3",
"       </sub>",
"      </td>",
"      <td class=\"subtitle1\">",
"       TSH",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other manifestations",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RTH",
"      </td>",
"      <td>",
"       &uarr; &uarr;",
"      </td>",
"      <td>",
"       &uarr; N",
"      </td>",
"      <td>",
"       &uarr; &uarr;",
"      </td>",
"      <td>",
"       N, sl &uarr;",
"      </td>",
"      <td>",
"       ADD Tachycardia, goiter",
"      </td>",
"      <td>",
"       <em>",
"        TR",
"        <sub>",
"         &beta;",
"        </sub>",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       THCTD*",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &uarr; &uarr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       N, sl &uarr;",
"      </td>",
"      <td>",
"       Severe psychomotor impairment",
"      </td>",
"      <td>",
"       <em>",
"        MCT8",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       THMD",
"      </td>",
"      <td>",
"       &uarr; &uarr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &uarr; &uarr;",
"      </td>",
"      <td>",
"       N, sl &uarr;",
"      </td>",
"      <td>",
"       Growth delay, male infertility",
"      </td>",
"      <td>",
"       <em>",
"        SBP2",
"       </em>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     THCTD: thyroid hormone transport defect; THMD: thyroid hormone metabolism defect; sl: slight; N: normal.",
"     <br>",
"      &uarr;: increased; &darr;: decreased.",
"      <br>",
"       * Males.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32731=[""].join("\n");
var outline_f31_61_32731=null;
var title_f31_61_32732="Systemic effects of elevated intraabdominal pressure";
var content_f31_61_32732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systemic effects of elevated intraabdominal pressure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Central nervous system",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; Intracranial pressure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Cerebral perfusion pressure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cardiac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypovolemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Cardiac output",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Venous return",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; PCWP and CVP",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; SVR",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Pulmonary",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; Intrathoracic pressure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; Peak inspiratory pressure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; Airway pressures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Compliance",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; PaO",
"          <sub>",
"           2",
"          </sub>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; PaCO",
"          <sub>",
"           2",
"          </sub>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; Shunt fraction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &uarr; Vd/Vt",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Gastrointestinal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Celiac blood flow",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; SMA blood flow",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Mucosal blood flow",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; pHi",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Renal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Urinary output",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Renal blood flow",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; GFR",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Hepatic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Portal blood flow",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Mitochondrial function",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Lactate clearance",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Abdominal wall",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Compliance",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          &darr; Rectus sheath blood flow",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32732=[""].join("\n");
var outline_f31_61_32732=null;
var title_f31_61_32733="Physical findings in the hypertensive child";
var content_f31_61_32733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical examination findings associated with possible etiology of hypertension in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physical examination finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Height and weight",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obesity",
"       </td>",
"       <td>",
"        Essential hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Truncal obesity",
"       </td>",
"       <td>",
"        Consider Cushing's syndrome, Steroid Rx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Growth retardation",
"       </td>",
"       <td>",
"        Consider chronic renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Vital signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tachycardia",
"       </td>",
"       <td>",
"        Catecholamine excess or hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BP&nbsp;differences in&nbsp;extremities",
"       </td>",
"       <td>",
"        If upper extremity BP &gt; lower extremity BP, consider coarctation of aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Head and neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elfin facies",
"       </td>",
"       <td>",
"        Williams syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moon facies",
"       </td>",
"       <td>",
"        Cushing syndrome,&nbsp;corticosteroid therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyroid enlargement",
"       </td>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Webbed neck",
"       </td>",
"       <td>",
"        Turner syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tonsillar hypertrophy",
"       </td>",
"       <td>",
"        Sleep-disordered breathing, sleep apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Eye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinal changes",
"       </td>",
"       <td>",
"        Suggest severe HTN and secondary etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papilledema",
"       </td>",
"       <td>",
"        Intracranial HTN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne, hirsutism, striae",
"       </td>",
"       <td>",
"        Cushing syndrome, Steroid Rx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caf&eacute;-au-lait spots and/or neurofibromas",
"       </td>",
"       <td>",
"        Neurofibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ash leaf spots and/or adenoma sebaceum",
"       </td>",
"       <td>",
"        Tuberous sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Rash",
"       </td>",
"       <td>",
"        Secondary renal disease: lupus,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Henoch-Sch&ouml;nlein purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acanthrosis nigricans",
"       </td>",
"       <td>",
"        Type 2 diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Murmur",
"       </td>",
"       <td>",
"        Coarctation of the aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apical heave",
"       </td>",
"       <td>",
"        L ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal bruit",
"       </td>",
"       <td>",
"        Reno-vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mass",
"       </td>",
"       <td>",
"        Hydronephrosis, polycystic kidney disease, renal tumors, neuroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulse",
"       </td>",
"       <td>",
"        LE pulse &lt; UE suggest coarctation of aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Traction/casts",
"       </td>",
"       <td>",
"        Orthopedic manipulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymmetry of limbs",
"       </td>",
"       <td>",
"        Beckwith-Wiedeman syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arthritis",
"       </td>",
"       <td>",
"        Henoch-Sch&ouml;nlein purpura, collagen vascular disease (lupus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle weakness",
"       </td>",
"       <td>",
"        Liddle syndrome, Hyperaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ascending paralysis",
"       </td>",
"       <td>",
"        Guillain-Barre syndrome, polio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diminished pain response",
"       </td>",
"       <td>",
"        Familial dysautonomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ambiguous/virilization",
"       </td>",
"       <td>",
"        Adrenal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advanced puberty",
"       </td>",
"       <td>",
"        Intracranial tumors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from the Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute. National Institutes of Health. May 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32733=[""].join("\n");
var outline_f31_61_32733=null;
var title_f31_61_32734="Manifestations of PCOS";
var content_f31_61_32734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manifestations of polycystic ovary syndrome in approximate proportion to their relative incidence and coincidence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneous symptoms include hirsutism, acne or acanthosis nigricans. Anovulatory symptoms include amenorrhea, oligomenorrhea, dysfunctional uterine bleeding, and infertility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rosenfield RL. Current concepts of polycystic ovary syndrome. Ballieres Clin Obstet Gynaecol 1997; 11:307. Copyright &copy; 1997 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32734=[""].join("\n");
var outline_f31_61_32734=null;
var title_f31_61_32735="Nail grinder 2";
var content_f31_61_32735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail grinder (Dremel)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_61_32735=[""].join("\n");
var outline_f31_61_32735=null;
